https://www.pharmaradar360.com hourly 1 https://www.pharmaradar360.com/news hourly 0.95 https://www.pharmaradar360.com/regulators daily 0.9 https://www.pharmaradar360.com/trials daily 0.85 https://www.pharmaradar360.com/pipeline daily 0.9 https://www.pharmaradar360.com/drug-approvals daily 0.9 https://www.pharmaradar360.com/journals weekly 0.8 https://www.pharmaradar360.com/pharma-companies weekly 0.8 https://www.pharmaradar360.com/specialties weekly 0.8 https://www.pharmaradar360.com/sources weekly 0.8 https://www.pharmaradar360.com/newsrooms weekly 0.8 https://www.pharmaradar360.com/pharma-tools weekly 0.8 https://www.pharmaradar360.com/pharma-communities weekly 0.75 https://www.pharmaradar360.com/pro weekly 0.75 https://www.pharmaradar360.com/tools weekly 0.7 https://www.pharmaradar360.com/about monthly 0.5 https://www.pharmaradar360.com/privacy yearly 0.35 https://www.pharmaradar360.com/support monthly 0.35 https://www.pharmaradar360.com/disclaimer yearly 0.35 https://www.pharmaradar360.com/drug/pembrolizumab daily 0.9 https://www.pharmaradar360.com/drug/semaglutide daily 0.9 https://www.pharmaradar360.com/drug/tirzepatide daily 0.9 https://www.pharmaradar360.com/drug/trastuzumab-deruxtecan daily 0.9 https://www.pharmaradar360.com/drug/osimertinib daily 0.9 https://www.pharmaradar360.com/drug/nivolumab daily 0.9 https://www.pharmaradar360.com/drug/dupilumab daily 0.9 https://www.pharmaradar360.com/drug/risankizumab daily 0.9 https://www.pharmaradar360.com/drug/lecanemab daily 0.9 https://www.pharmaradar360.com/drug/atezolizumab daily 0.9 https://www.pharmaradar360.com/article/staunch-biotech-competition-spurs-new-secretive-tactics-shifts-investor-approach-bef2c24268292855 2026-09-11T10:37:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/poland-s-case-against-eu-wastewater-rules-boosted-by-advocate-general-opinion-0cb3bd178f9e4c11 2026-09-11T10:18:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/estates-safety-fund-initial-schemes-and-associated-funding-allocations-2026-to-2-578511fd55580096 2026-09-11T09:54:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/set-yourself-up-for-a-strong-2027-2-pharmaceutical-stocks-to-buy-in-september-7c5df69ea3cb3fa3 2026-09-11T09:53:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-tartan-army-to-biotech-deepening-scotland-s-ties-with-boston-through-new-li-882a8830a7c1ede8 2026-09-11T09:40:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/set-yourself-up-for-a-strong-2027-2-pharmaceutical-stocks-to-buy-in-september-8cc69ed199f1afbf 2026-09-11T09:35:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/head-of-german-venture-fund-sees-big-potential-in-danish-biotech-but-investors-a-cbacdcd980c6a8e4 2026-09-11T09:35:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/are-you-working-with-the-non-clinical-package-for-clinical-trial-applications-se-381cb66138accd14 2026-09-11T09:34:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/rewriting-the-rules-of-genetic-medicine-with-trna-therapeutics-beyond-biotech-aee67803a2f832f6 2026-09-11T09:33:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/key-approvals-positive-study-results-and-a-partnership-deal-to-fast-track-new-me-4a3eb1cbd863abcd 2026-09-11T09:25:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-regulators-ask-when-ai-touches-a-drug-application-601c189441f030a0 2026-09-11T09:25:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/trial-misses-prompt-shake-up-call-from-major-novartis-stockholder-9b04ea1f348cb183 2026-09-11T09:25:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/shanghai-henlius-biotech-inc-announces-acceptance-of-new-drug-application-for-12-deaaab0cc42dfe4b 2026-09-11T09:20:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/meet-the-under-35s-shaping-the-future-of-biotech-0e01cfbafd7d371b 2026-09-11T09:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/aprecia-pharmaceuticals-am-is-an-important-expansion-of-the-pharmaceutical-manuf-fa4992349a80da17 2026-09-11T08:51:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/veraxa-biotech-vrxa-insider-trading-activity-2026-249623a1453a3bf2 2026-09-11T08:46:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/moderna-begins-phase-1-clinical-trial-of-ebola-vaccine-against-strain-behind-drc-0f15edae8af6e558 2026-09-11T08:26:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-advisers-narrowly-vote-to-add-6-peptides-to-a-drug-compounding-list-what-s-n-05eb0af1ede61b6f 2026-09-11T08:26:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/reporter-s-notebook-k-biopharma-licensing-deals-are-getting-better-not-just-bigg-744ac6deb31a7e39 2026-09-11T08:24:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-13-september-2026-1016782b910b7d0c 2026-09-11T08:22:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/astadaily-earns-purity-award-from-clean-label-project-d798f43275060d64 2026-09-11T08:20:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/jpmorgan-initiates-dianthus-stock-at-overweight-135-target-76d704bda903e96f 2026-09-11T08:12:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-students-must-step-out-of-comfort-zones-embrace-multiple-roles-suchitra-bd66bfb839665905 2026-09-11T07:57:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-clears-prelude-s-prt13722-phase-1-trial-in-hr-positive-breast-cancer-33a29eff5efb8a93 2026-09-11T07:33:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/limitless-biotech-coupon-code-pct15-save-15-on-research-peptides-b07e64035e883a26 2026-09-11T07:22:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/kenanga-launches-world-first-hang-seng-biotech-index-structured-warrants-258d523c61bb1937 2026-09-11T07:16:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/marquis-who-s-who-honors-kenneth-hesterman-for-expertise-in-pharmaceutical-accou-4cd9960720360d81 2026-09-11T07:02:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-excipients-market-to-reach-usd-24-88-billion-by-2035-at-8-1-cagr-e55ec71af1e14859 2026-09-11T06:57:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-says-closely-watched-cholesterol-study-failed-to-meet-goal-c974947767e107ee 2026-09-11T06:45:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/phase-3-study-shows-aqivc-superior-to-comparators-in-older-adults-b7ea1dfa91dfde4e 2026-09-11T06:38:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/reg-rtw-biotech-opp-additional-investment-in-encoded-therapeutics-06ce266c777880ac 2026-09-11T06:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/orzeyful-approval-might-change-the-case-for-investing-in-takeda-stock-8b50302be3cb1bfe 2026-09-11T05:58:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-strong-biotech-ip-strategies-get-right-and-where-weak-ones-break-down-a2b121fe65165341 2026-09-11T05:43:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/comment-climate-change-threatens-pharmaceutical-companies-6987587302b518a2 2026-09-11T05:13:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/former-head-of-takeda-pharmaceutical-dies-at-80-6fc269c48465eb75 2026-09-11T05:03:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/active-biotech-ab-publ-sto-acti-is-breakeven-near-585e562e6ced9952 2026-09-11T04:30:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-partially-halts-trials-of-sk-biopharmaceuticals-epilepsy-drug-candidate-e77116af26fe1e1f 2026-09-11T04:17:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/west-pharmaceutical-services-senior-vp-favorite-sells-2-77m-in-stock-9fe9896a7541d2cb 2026-09-11T04:16:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/jiangsu-handian-biotech-lands-tens-of-millions-of-yuan-in-strategic-round-89239b47de33a798 2026-09-11T04:01:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/ex-takeda-pharmaceutical-head-hasegawa-dies-at-80-07ac3ad58f8939ed 2026-09-11T03:54:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/paradigm-biopharmaceuticals-asx-par-draws-final-us-2-million-tranche-as-phase-3-a44324072bfb26c8 2026-09-11T03:18:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/paradigm-biopharmaceuticals-secures-additional-funding-for-phase-3-clinical-tria-ddb4fb8de8310392 2026-09-11T03:07:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-halts-sk-biopharm-s-opcalim-novartis-12-billion-drug-fails-phase-3-0ab09b28ac07fe98 2026-09-11T03:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/laser-therapy-offers-new-hope-for-inoperable-pancreatic-tumors-aa7039f94cc04951 2026-09-11T03:01:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/viking-therapeutics-aims-high-at-92-target-but-clinical-risks-remain-cdae87387dc82248 2026-09-11T02:54:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/more-than-28-000-bottles-of-blood-pressure-drug-recalled-fda-11bf9d424e5e5c88 2026-09-11T02:31:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-stocks-need-a-shot-in-the-arm-after-brutal-july-could-astrazeneca-bristo-0c28c1010a46e800 2026-09-11T02:30:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/agenda-for-november-2026-cancer-treatments-ctac-meeting-3a6d1f5f98e260f8 2026-09-11T02:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/genscript-biotech-to-place-77-1-million-shares-at-hk-30-50-per-share-586a45444917dbb9 2026-09-11T01:29:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/annual-iipa-debate-2026-ku-fda-plan-major-food-safety-awareness-push-in-j-k-415bf82849db4727 2026-09-11T01:24:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/is-teva-pharmaceutical-industries-nyse-teva-still-a-bargain-or-fully-priced-22afb570e071b7c5 2026-09-11T01:16:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-fda-pauses-new-enrollment-in-biohaven-s-epilepsy-drug-trials-f4e06e3e7cd27817 2026-09-11T01:05:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/megazonecloud-begins-building-hanmi-pharmaceutical-s-quality-assurance-ai-agent-34906fa2a5c01536 2026-09-11T00:06:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-7584d6fa6e4ae920 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-9ef22d0b3e10454a 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-cdd95bf3559e4cec 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-0c0fb15eb6c3b812 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-eaeaad2b1757f369 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-fec20d0ecf6e8a08 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-e3f885ccf75002b9 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-387b96369039a218 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-7f5456fbff2a09db 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-afe80eb92a8c9c39 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-a6fe3f8b4d203625 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-68ff035afccb0a3e 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-ea300a76aa4bfbd0 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/home-page-9844da1238f74937 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-heart-lung-and-blood-institute-notice-of-meeting-a3006d086a794e13 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-devices-cardiovascular-devices-classification-of-the-cardiovascular-mach-212eaf111483ed36 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-omb-review-comment-reque-577ad723f444fe54 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/emran-mohammad-rn-aprn-cnp-decision-and-order-c222547fc36d6725 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/joseph-john-stubbers-iii-d-o-decision-and-order-56e3d57bd217be2e 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cheryl-white-n-p-decision-and-order-6910fc9ec09361e7 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/craig-cohen-dpm-decision-and-order-bac086480e607f05 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/notice-of-supplemental-funding-appalachian-region-healthcare-support-program-eb7a15e20f6e765d 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/notice-of-supplemental-funding-infant-toddler-court-program-state-awards-556a097130f48a79 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-public-comment-requ-cbd46bd70ec39a02 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/amending-over-the-counter-monograph-m020-sunscreen-drug-products-for-over-the-co-bf1f21ba8881a138 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-med-93720515e76d644f 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-c7cf00b962ad7623 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/notice-of-supplemental-funding-rural-hospital-stabilization-pilot-program-f42ef2358c137743 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-institute-on-aging-amended-notice-of-meeting-05a388dc6e88ab98 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-institute-of-diabetes-and-digestive-and-kidney-diseases-amended-notice-943f33d3924a19c8 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-e4c7ec9101c7b4ed 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-services-do-people-seek-when-they-visit-a-community-pharmacy-care-clinic-d0b530ddc5e44386 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/managing-patients-with-heart-failure-a-contemporary-practice-tool-for-pharmacist-7c408d6b46d4237c 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medication-safety-in-indigenous-communities-challenges-and-interventions-1bf49ca019f7d0e2 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ten-year-analysis-of-publications-by-quebec-hospital-pharmacists-8f6c95173b5e694f 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-related-problems-in-older-adults-with-mild-cognitive-impairment-or-dementia-96f624acc8f4f4a9 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/management-of-a-patient-with-a-ticagrelor-rosuvastatin-interaction-an-algorithm-9d231ffd5b5bc159 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-call-for-the-generalist-pharmacist-bdb545612f6c918f 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/late-onset-multiple-acyl-coa-dehydrogenase-deficiency-madd-glutaric-acidemia-typ-26ad462a8ff18b6e 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/successful-management-of-generalized-drug-influenced-gingival-enlargement-a-clin-a0dff0eeba02fdca 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-phenotypes-and-factors-associated-with-systemic-involvement-in-pediatri-bb23bbedc93d5e22 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-ictal-interictal-continuum-a-comprehensive-review-for-the-clinical-epileptol-1d28a0773cd7a283 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/knowledge-attitudes-and-practices-regarding-hypertension-prevention-among-medica-95ce3ccfb7d13a35 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/acupuncture-care-for-a-patient-with-tennis-elbow-lateral-elbow-tendinopathy-a-ca-55448e3e6a6b64ce 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/i-ll-see-it-when-i-believe-it-73965d6ba86bbf24 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-practitioner-s-guide-to-ericksonian-choice-architecture-7ba5e46554ae733e 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effectiveness-of-olfactory-training-and-topical-corticosteroids-for-persistent-p-284ef17782a9bce4 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/future-directions-b7312a04957ae1cb 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/teaching-the-invisible-a-game-based-simulation-for-learning-health-care-economic-7ea5cdfe5504fe20 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pre-diagnostic-identification-of-cholestatic-liver-diseases-using-integrated-cli-89d880bf052825c6 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/localization-of-advanced-drug-delivery-manufacturing-in-saudi-arabia-through-tec-a5d3d641a0ae9b7d 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/predictive-analysis-of-social-determinants-of-health-in-posterior-cervical-spine-990d69caca0e348f 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-between-physical-therapy-and-mortality-in-older-patients-with-heart-9c687d7a8b736236 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hydrus-microstent-combined-with-cataract-surgery-in-pseudoexfoliation-glaucoma-v-da281f09101151ea 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/functional-status-and-postoperative-outcomes-after-left-pancreatectomy-for-pancr-ece63d7def3a3618 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/diagnostic-approach-and-therapeutic-management-of-spontaneous-esophageal-perfora-729725021ca6e7c5 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-implementation-and-clinical-validation-of-a-whole-genome-sequencing-non-inva-5efd029892d9731c 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/risk-stratification-of-acute-symptomatic-anterior-circulation-intracranial-ather-060335b18fc361ee 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-clinical-study-of-simotang-oral-liquid-combined-with-shenque-acupoint-applicat-d4b5d7677424f285 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fusion-level-selection-in-posterior-hemivertebra-resection-for-congenital-scolio-4356d58d5169b806 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/rethinking-ai-in-clinical-decision-support-a-framework-for-reciprocal-human-ai-i-1420c6c6866df483 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-efficacy-of-radix-arnebiae-oil-in-patients-undergoing-incision-and-drai-58f0e461772494f1 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fetal-behavior-as-a-window-to-later-gross-motor-function-a-10-year-follow-up-of-c8f670e65987c96e 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-laboratory-criteria-for-a-differentiated-approach-to-the-management-d489377a752957d5 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/efficacy-of-dapagliflozin-in-the-treatment-of-patients-with-signs-of-cardio-rena-d4a6bb4196d21d84 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-rationale-for-individualizing-secondary-prevention-in-patients-with-ath-c7a775dd082043ba 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-characteristics-and-surgical-outcomes-of-split-cord-malformations-a-ret-a259bf8535951c1f 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrating-computed-tomography-and-magnetic-resonance-imaging-education-into-a-916bc317b1b11c9c 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/preparation-and-characterization-of-chitosan-co-acrylamide-hydrogels-for-control-6272337bb2bce876 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/enhancing-guideline-directed-medical-therapy-at-discharge-through-collaborative-61c425f8c65f8565 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-relevance-of-accuracy-in-in-house-3d-printing-in-craniomaxillofacial-su-5d29ff74d526eef8 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-theory-based-health-education-intervention-in-improving-exclusive-brea-3c22484e4d298979 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluation-of-the-feasibility-usability-and-preliminary-effects-of-an-mhealth-in-61c938230b152285 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-of-cavaterm-thermal-balloon-endometrial-ablation-in-women-with-9a5696678c3b99a8 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/alveolar-ridge-preservation-using-advanced-platelet-rich-fibrin-versus-concentra-642458687bb7b17c 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-low-dose-esketamine-on-quality-of-recovery-after-gynecologic-laparosco-9565882e22d28941 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/salivary-lysozymes-anti-inflammatory-cardiac-medications-and-cardiovascular-mort-595fc7d8250f6e70 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-association-between-hormonal-contraceptives-and-lower-extremity-injuries-in-7f2bf0b2935043e0 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/uncertainty-and-novel-clinical-trial-designs-in-oncology-when-should-equipoise-m-9d09e54cf8511c76 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mitral-regurgitation-and-severe-aortic-stenosis-clinical-characteristics-prognos-56a6b86519668248 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/spatiotemporal-mapping-of-tertiary-lymphoid-structure-heterogeneity-shapes-immun-b878c7a6750a845e 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/lignan-rich-norway-spruce-i-picea-abies-i-resin-extract-exhibits-anti-inflammato-bbbefd8591a7808a 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/alcohol-and-other-drug-policies-for-health-care-workplaces-evaluation-of-the-con-e99cec33373f8f7b 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrating-public-health-advertising-and-the-health-belief-model-to-predict-dia-a0939aee5e67c757 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/interesting-hurdles-in-the-solution-of-pharmaceutical-crystal-structures-using-p-3e514e35adab43a8 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-factors-are-associated-with-shoulder-joint-pain-in-male-swimmers-including-2d4ac870140b4056 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/optimized-dosing-of-momelotinib-in-myelofibrosis-through-quantitative-medicine-a-82759c408af8a2d1 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/implementing-structured-and-collaborative-clinical-planning-for-comprehensive-hi-2ee6f77428200007 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-daffodils-to-drug-leads-amaryllidaceae-alkaloids-target-protein-translation-d152f81dc448462f 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/maladaptive-movement-in-eating-disorders-clinical-correlates-and-cross-cultural-88f05d3f85a94292 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gut-microecology-and-cardiovascular-disease-core-pathogenic-mechanisms-and-clini-3c2babc6119fff71 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/oligoclonal-band-count-as-a-marker-of-mri-lesion-burden-and-clinical-profile-in-750eee9cb00a292e 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-mri-features-associated-with-remission-following-biological-therapy-0d857f7086779929 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/repeated-perioperative-hypersensitivity-reactions-and-positive-challenge-testing-a6d40ff19fd054a0 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/safety-of-nonsteroidal-anti-inflammatory-drug-use-in-traumatic-brain-injury-579799c9f9af014a 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmacokinetics-of-loading-dose-vigabatrin-administered-via-enteral-tube-in-par-90af192c98b082d8 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-s-2026-ipos-deliver-broad-gains-through-august-5be01e38f285a85a 2026-09-10T23:40:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ctt-pharmaceutical-holdings-ceo-ryan-khouri-buys-175-in-stock-ba8ba3e61a362f04 2026-09-10T23:31:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-trials-new-mrna-cancer-vaccine-plus-keytruda-sharply-improves-melanoma-77a6de9d73d0071d 2026-09-10T22:14:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-withdraws-publication-of-covid-shingles-vaccine-research-findings-0c9137b444e2e92a 2026-09-10T22:07:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/presidential-leadership-series-features-trustee-and-former-takeda-ceo-christophe-38714faec7ed3737 2026-09-10T21:57:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/cpc-biotech-multiply-labs-develop-robot-ready-cell-therapy-connector-21a5a057220ff310 2026-09-10T21:54:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/west-pharmaceutical-services-sr-vp-chief-hr-officer-sold-shares-worth-over-2-7m-e4a012d0bc83cc78 2026-09-10T21:40:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/west-pharmaceutical-nyse-wst-hr-chief-sells-stock-outside-a-10b5-1-plan-f09f4eb3b8e82826 2026-09-10T21:37:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/european-regulators-prepare-the-pharma-industry-for-future-changes-as-legislatio-fea13585a4f31be1 2026-09-10T21:32:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/new-phase-2-clinical-trial-initiating-in-2027-evaluating-psilocybin-assisted-the-b453b9741c0dd011 2026-09-10T21:10:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/david-samra-calls-for-novartis-board-shake-up-pharmexec-d325baf3d1a4dd3e 2026-09-10T21:06:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-stock-outperforms-competitors-on-strong-trading-8d201788bc6ff87c 2026-09-10T21:04:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/krystal-biotech-at-cantor-healthcare-conference-pipeline-gains-pace-da48474dd512d462 2026-09-10T20:42:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32 2026-09-10T20:26:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/west-pharmaceutical-nyse-wst-awards-ceo-37k-options-and-14-8k-rsus-vesting-throu-02890534117bc52a 2026-09-10T19:40:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/precision-trading-with-fortress-biotech-inc-9-375-series-a-cumulative-redeemable-7b2183f89cc3ac84 2026-09-10T19:10:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/committee-will-weigh-biotech-innovation-against-security-risks-6d75b2b5f7c94bf9 2026-09-10T18:42:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/biohaven-shares-plunge-as-fda-halts-new-enrollment-in-epilepsy-drug-trials-ba8d221d153c02a0 2026-09-10T18:41:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/encoded-secures-275m-for-dravet-syndrome-gene-therapy-ac2b33bda3009e77 2026-09-10T18:37:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-seeks-public-input-on-advancing-botanical-drug-development-ed74359bca572fc5 2026-09-10T18:25:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-declares-quarterly-dividend-260df77eb2bfb636 2026-09-10T18:25:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/5-best-psychedelic-stocks-for-2026-and-how-to-invest-723c0a3c104e3b21 2026-09-10T18:18:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/chemical-structure-formula-and-name-support-written-description-of-pharmaceutica-1d77f969ae2d3e5c 2026-09-10T18:11:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/quantum-biopharma-s-lucid-ms-advances-toward-phase-2-multiple-sclerosis-trial-af-2e6eaca0773422e8 2026-09-10T17:53:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/hplc-degasser-upgraded-biotech-fluidics-launches-the-degasi-ng-platform-28b7579689b125bf 2026-09-10T17:03:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-products-with-device-only-patents-a-cross-sectional-analysis-5b12204246d6eec3 2026-09-10T16:47:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/anmat-actualiza-los-criterios-regulatorios-para-software-como-dispositivo-medico-ce78e29882f4f325 2026-09-10T16:46:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-drug-shows-significant-reductions-in-menstrual-migraine-days-0a66926b0c3b14b1 2026-09-10T16:41:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-news-from-around-the-world-96b51f3fd7c4a507 2026-09-10T16:40:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/seattle-biotech-brainchild-bio-raises-116m-to-advance-car-t-therapy-for-childhoo-6c114812ad208cfb 2026-09-10T16:34:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/nhs-injury-costs-recovery-scheme-april-2025-to-march-2026-02e29b54f45a8fc7 2026-09-10T16:26:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/best-biotech-stocks-to-add-to-your-watchlist-september-10th-d8ab2eff220ca406 2026-09-10T16:04:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/xocova-offers-new-post-exposure-covid-19-prevention-option-for-adolescents-180741a4ba145920 2026-09-10T15:57:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/hsil-extends-biotech-index-to-malaysia-s-warrant-market-7d7be353577cf20e 2026-09-10T15:26:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/kala-shankle-on-what-comes-next-for-national-licensure-74efa622bca91473 2026-09-10T15:23:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/minister-agrees-to-review-pharmacy-amendments-to-health-bill-46a2c884d11eb4a4 2026-09-10T15:19:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/ai-changes-the-how-not-the-what-ccddb8218dba7492 2026-09-10T15:15:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/roivant-at-citi-summit-cash-rich-biotech-leans-on-three-pillars-60ac4a42be1a796f 2026-09-10T14:55:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/phase-3-trial-of-experimental-dm1-treatment-fails-to-hit-main-goal-47fea7492ee4aa03 2026-09-10T14:54:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-fda-pauses-new-enrollment-in-biohaven-s-epilepsy-drug-trials-2130c9870ed50f98 2026-09-10T14:45:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/burning-rock-biotech-limited-reports-earnings-results-for-the-second-quarter-end-fe9932e3452b9015 2026-09-10T14:37:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-fda-pauses-new-enrollment-in-biohaven-s-epilepsy-drug-trials-dfd4d9a9539fb316 2026-09-10T14:36:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/fifth-circuit-judges-press-louisiana-on-standing-as-mifepristone-stays-available-7803e41623ffd424 2026-09-10T14:30:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/high-consequence-infectious-disease-country-specific-risk-11ed7e663ad962ce 2026-09-10T14:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-and-marburg-haemorrhagic-fevers-outbreaks-and-case-locations-16b29cdb0bb31831 2026-09-10T14:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/syndromic-surveillance-weekly-summaries-for-2026-45747e3878253def 2026-09-10T14:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/remote-health-advice-weekly-bulletins-for-2026-0b8fbceac342c05c 2026-09-10T14:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/outbreaks-under-monitoring-in-2026-eb6ae222898106b1 2026-09-10T14:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-ambulance-syndromic-surveillance-weekly-bulletins-2026-6dee157afd1fba75 2026-09-10T14:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/gp-out-of-hours-syndromic-surveillance-weekly-bulletins-for-2026-f212a5a75078c06e 2026-09-10T14:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/gp-in-hours-weekly-bulletins-for-2026-dfebf391f225843d 2026-09-10T14:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/emergency-department-weekly-bulletins-for-2026-08abcdde2881ef86 2026-09-10T14:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-past-endpoints-11-winners-fared-as-the-biotech-industry-rebounded-b43f9ce8182c04f8 2026-09-10T14:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-security-market-competitive-landscape-analyzed-across-leading-glo-ae872b3a3ec772bd 2026-09-10T14:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/greater-philadelphia-regional-life-sciences-roundup-september-10-2026-a692fddd69a19c9d 2026-09-10T14:28:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/glenmark-and-south-piedmont-open-2-7-million-pharmaceutical-training-facility-0b4260fbc2643d82 2026-09-10T14:18:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-cracks-down-on-unsafe-food-banned-products-17cbcad470576ff1 2026-09-10T14:14:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/stalled-generous-globe-and-guard-initiatives-create-international-pricing-uncert-01e4dff956d74dff 2026-09-10T14:13:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-health-equity-champions-can-learn-from-pharmaceutical-sales-9d780c13222a1501 2026-09-10T13:59:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-places-partial-hold-on-biohaven-s-ion-channel-drug-f305595bf9c3c703 2026-09-10T13:58:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/environmental-monitoring-following-the-grenfell-tower-fire-85d5cc3f2b36adbc 2026-09-10T13:52:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-raids-11-food-units-in-thane-seizes-materials-worth-rs-20-48-lak-9f75fd7cc7276ce7 2026-09-10T13:47:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/frazier-life-sciences-nets-1-1b-in-long-running-fund-aimed-at-small-midsize-biot-6cbd4c5bcf9742eb 2026-09-10T13:44:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/adarx-pharmaceuticals-seeks-ipo-on-strong-collaboration-deal-with-abbvie-pending-5dba419255f531e9 2026-09-10T13:41:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/imunon-enters-cooperative-research-and-development-agreement-with-national-cance-9c28ffcdb1c0cf0f 2026-09-10T13:40:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-expands-bayer-lung-cancer-drug-approval-71178ea7131e5c0a 2026-09-10T13:39:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/scenic-biotech-appoints-renowned-neurology-drug-development-leader-dr-judith-wal-b0c70810964568e8 2026-09-10T13:33:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/cullinan-therapeutics-inc-common-stock-cgem-stock-price-news-quote-history-9e08eae6d576bb60 2026-09-10T13:33:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/samsung-biologics-signs-usd-262-million-manufacturing-agreement-with-european-ph-d2defa9f379bb988 2026-09-10T13:32:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/imunon-enters-cooperative-research-and-development-4ff7c827c11dfc18 2026-09-10T13:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/west-pharmaceutical-services-at-wells-fargo-conference-growth-outlook-lifts-7e95f35a8d9d2806 2026-09-10T13:29:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/scynexis-appoints-sanjay-subramanian-cfo-as-biotech-advances-rare-disease-pipeli-7ffff17544555b0f 2026-09-10T13:28:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/major-expansion-of-community-mental-health-support-across-england-a2cb994842375abb 2026-09-10T13:27:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/mrna-cancer-vaccines-biggest-barriers-to-market-5a32cb9618b921d8 2026-09-10T13:26:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/takeda-s-long-serving-r-d-chief-andy-plump-to-retire-in-wake-of-pipeline-success-59af07bbf36e86fb 2026-09-10T13:25:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/frazier-life-sciences-adds-1-1b-to-biotech-public-fund-lifting-it-to-2-8b-e142f1ed47f39964 2026-09-10T13:25:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/burning-rock-biotech-releases-q2-2026-financial-results-8819331f3d074a9a 2026-09-10T13:22:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/update-starton-therapeutics-to-present-at-medinvest-biotech-pharma-conference-d467c5ff3d6873eb 2026-09-10T13:19:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-pre-market-movers-tnon-aeon-surge-coo-cdt-slide-a99c6eadfee151c8 2026-09-10T13:17:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biovie-seeks-fda-meeting-to-plan-phase-3-trial-for-parkinson-s-drug-candidate-4c45ecc8dc428588 2026-09-10T13:16:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/25f1670-gloflon-i-v-catheter-with-injection-valves-wings-20g-1-1-x-33mm-666903112fb8586e 2026-09-10T13:12:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/cannara-biotech-secures-58m-credit-facility-with-bmo-and-td-5c15a8e996887473 2026-09-10T13:07:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/latest-figures-highlight-ongoing-meningitis-b-risk-for-students-d7de382570d1ec44 2026-09-10T13:06:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/burning-rock-q2-revenue-falls-9-3-to-rmb134-7m-cafe7127e11ce51e 2026-09-10T13:04:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-2026-to-2027-46b78a2386536090 2026-09-10T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-reports-2026-to-2027-season-32f74fa23fd23c69 2026-09-10T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/no-treatment-is-approved-for-menstrual-migraine-abbvie-s-drug-cut-migraine-days-6a69b46a841b8f13 2026-09-10T12:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-extends-migraine-leadership-with-positive-phase-3-atogepant-results-in-me-aa42924a07011e55 2026-09-10T12:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharma-pulse-dhl-s-new-singapore-hub-and-pharma-rethinks-go-to-market-6f1e39d1bd379b78 2026-09-10T12:53:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/geovax-provides-nasdaq-listing-update-and-reaffirms-focus-on-advancing-strategic-e2e455613a5a2210 2026-09-10T12:37:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/unlocking-cell-surface-protein-research-with-site-specific-labelling-4b2c27c5d4f0630d 2026-09-10T12:34:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/oncolytics-biotech-reports-preclinical-pelareorep-activity-maintained-with-ras-i-acb108f11ddc1118 2026-09-10T12:21:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/daesang-expands-into-pharmaceutical-grade-amino-acids-7525345f8975eea5 2026-09-10T12:15:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/an-experimental-cancer-treatment-combination-reduced-tumor-growth-in-early-tests-915d2ac78c60b6c6 2026-09-10T12:15:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/an-investigational-cell-therapy-for-alzheimer-s-and-parkinson-s-will-be-presente-9bd92b46dfeadd3f 2026-09-10T12:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-look-at-cleanassure-by-freudenberg-medical-1781dee31e7a4af8 2026-09-10T12:00:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/imn-screws-system-advanced-locking-screw-ec5f499d9db6b051 2026-09-10T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/generic-acetaminophen-by-teva-recalled-because-it-may-contain-foreign-material-7343823d673bcc9f 2026-09-10T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/dxc-500i-clinical-analyzer-and-dxc-500-au-clinical-chemistry-analyzer-0e5e9773dfcba50d 2026-09-10T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/centricity-high-acuity-anesthesia-2ada63128acd97cc 2026-09-10T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/data-on-five-year-remission-with-a-myeloma-treatment-will-be-presented-in-scotla-a31339569a772091 2026-09-10T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-is-biohaven-pharmaceutical-stock-sliding-today-d8352213f625eea5 2026-09-10T11:46:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-booming-business-on-wall-street-would-love-more-biotechs-to-quietly-die-23a99c530fc41a86 2026-09-10T11:46:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/data-aggregation-drives-ai-s-impact-on-clinical-supply-chains-c09c4abbac6eea8f 2026-09-10T11:35:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/cervomed-announces-initial-results-from-the-phase-2a-clinical-trial-of-neflamapi-8e9e18b565ad084e 2026-09-10T11:34:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/3145507-hippokratis-10x20-ply-ref-1020121301-070cc64470b4812d 2026-09-10T11:33:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-hair-brand-vegamour-snapped-up-by-kvd-beauty-owner-belle-brands-9e5b5f7223daebe3 2026-09-10T11:30:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/cervomed-announces-initial-results-from-the-phase-2a-clinical-trial-of-neflamapi-93171a452257b7a9 2026-09-10T11:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/burning-rock-biotech-s-q2-revenue-falls-net-loss-widens-on-central-laboratory-we-3a2bfe5a57b7c6c6 2026-09-10T11:29:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/burning-rock-biotech-reports-second-quarter-2026-financial-results-and-business-3604b6a838f831f6 2026-09-10T11:20:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/prelude-therapeutics-receives-fda-clearance-of-investigational-new-drug-ind-appl-173e26866817c76e 2026-09-10T11:13:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/can-simulation-help-foundation-trainee-pharmacists-prepare-for-prescribing-754b389753a9f647 2026-09-10T11:12:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/migraine-and-acne-included-in-new-prescribing-pharmacy-first-pathways-3ea2469614a56a9c 2026-09-10T11:12:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/uzbekistan-pharmaceutical-output-reaches-uzs-3-5-trillion-in-seven-months-e698870d82152c1b 2026-09-10T11:10:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/phase-1-2-clinical-trial-of-opgx-best1-shows-positive-results-for-inherited-reti-693efb757e3769e0 2026-09-10T11:09:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/podcast-key-readouts-from-esc-and-ers-37928ee094726d75 2026-09-10T11:00:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/new-suicide-risk-research-will-join-five-posters-on-a-treatment-e30968146e5d4bba 2026-09-10T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sk-biopharm-s-in-licensed-epilepsy-drug-opcalim-hits-partial-fda-clinical-hold-58e7c243c85a1a2c 2026-09-10T10:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hhs-appoints-permanent-fda-cber-cder-heads-40d9e998d4d06de3 2026-09-10T10:52:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/spain-pushes-for-access-toolbox-in-eu-biotech-rules-1688a317e36915f9 2026-09-10T10:48:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/inauguration-ceremony-of-the-nafdac-pharmacist-reserve-group-3142b109dbb0e447 2026-09-10T10:45:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-appeals-court-skeptical-of-bid-to-curtail-abortion-pill-access-078244ed36863e9c 2026-09-10T10:40:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/join-the-danish-medicines-agency-s-atmp-open-house-c8681c32f51f75b3 2026-09-10T10:39:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-to-expect-from-uniqure-s-upcoming-huntington-s-gene-therapy-readout-e0aa083eeef3c734 2026-09-10T10:36:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/roivant-is-one-of-the-savviest-dealmakers-in-biotech-it-also-has-a-secret-weapon-c406bfe29c9a43b3 2026-09-10T10:36:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/squarepoint-ops-llc-sells-106-171-shares-of-ultragenyx-pharmaceutical-inc-rare-aaef604b00280d03 2026-09-10T10:16:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-prices-4-9-billion-senior-notes-offering-and-anno-b1e8ff5e4e7ab9df 2026-09-10T10:11:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/power-optimization-solution-ends-costly-grid-related-shutdowns-at-major-pharmace-895389c9339efb13 2026-09-10T10:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/active-pharmaceutical-ingredients-market-demand-insights-ee7be79d74ee8b32 2026-09-10T09:46:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/one-assessment-27-countries-how-eu-joint-reviews-work-afdce1a4bab2fa1a 2026-09-10T09:44:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/when-the-er-is-not-an-option-milestone-s-cmo-on-bringing-afib-rate-control-home-e2e99f9bbe1ee809 2026-09-10T09:36:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/takeda-pharmaceutical-co-ltd-takeda-announces-planned-retirement-of-president-of-cc51e8d4bc8214ff 2026-09-10T09:34:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/takeda-pharmaceutical-announces-planned-retirement-of-president-of-research-deve-57aa87713cda8888 2026-09-10T09:34:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/systech-launches-traceiq-0628e750134c6813 2026-09-10T09:33:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-ud-s-star-campus-is-helping-companies-foster-innovation-in-biotech-bfd0e22feb57c6cb 2026-09-10T09:31:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-growth-trust-stands-out-in-a-stronger-biotechnology-sector-0c5fc1ee6f1de77b 2026-09-10T09:24:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/me-therapeutics-stock-faces-downside-pressure-as-biotech-risk-and-preclinical-un-1ec2178796d0ffa0 2026-09-10T09:19:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biocorrx-inc-appoints-former-acting-white-house-drug-policy-director-richard-j-b-f65963320838259a 2026-09-10T09:16:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/yourgene-insight-dpyd-assay-gets-ivdr-accreditation-0f45b3e7e51c89f2 2026-09-10T09:10:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-places-partial-clinical-hold-on-sk-biopharm-s-epilepsy-drug-candidate-opacal-826dea09fcfc58cc 2026-09-10T09:10:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/mog-fda-35ed387f5c4715ce 2026-09-10T09:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/roche-announces-u-s-fda-grants-priority-review-for-enspryng-for-myelin-oligodend-399e802924ad2be2 2026-09-10T09:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/samsung-biologics-signs-350-8-billion-long-term-cmo-deal-with-european-pharmaceu-f69633ea36eaf3ad 2026-09-10T08:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-fluidics-launch-degasi-ng-platform-03359e408ef2f244 2026-09-10T08:47:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/dong-a-socio-holdings-to-rename-itself-dong-a-pharmaceutical-after-otc-merger-811dc3505dca9b48 2026-09-10T08:46:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-fluidics-upgrades-its-degasi-inline-degasser-range-2e8eb202eff2dd75 2026-09-10T08:35:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-evidence-matters-seema-meloni-on-making-data-meaningful-ec1cdcab294170da 2026-09-10T08:33:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/salmonella-outbreak-update-dbba55fa25793323 2026-09-10T08:30:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/mpox-clade-ib-and-clade-iib-outbreak-epidemiological-overview-99d096b3fc6f5884 2026-09-10T08:30:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/salmonella-statistical-releases-5659a2d745797007 2026-09-10T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/meningococcal-disease-laboratory-confirmed-cases-in-england-2025-to-2026-26816bdfcbfa7f60 2026-09-10T08:30:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/antimicrobial-resistance-awareness-toolkit-for-healthcare-providers-0c0f57c6f41d20ce 2026-09-10T08:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/venture-investor-danish-biotech-innovation-has-caught-up-with-sweden-3b75feb145abd779 2026-09-10T08:20:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-packaging-market-c2e9bc2e819d9a7b 2026-09-10T08:16:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-disease-caused-by-bundibugyo-virus-democratic-republic-of-the-congo-22eadb56d9fb8544 2026-09-10T08:16:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/gov-healey-eyes-changes-to-life-sciences-programs-as-early-stage-biotechs-strugg-17782bbe9a7546e8 2026-09-10T08:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/scenic-biotech-appoints-renowned-neurology-drug-development-leader-dr-judith-wal-e6c409ade4de9fa6 2026-09-10T07:51:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-6-september-2026-10a6be24e936e540 2026-09-10T07:34:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-quarterly-data-up-820ecbff0a7a966c 2026-09-10T07:29:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-quarterly-data-up-335870a76488db42 2026-09-10T07:28:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-quarterly-data-up-ae1ac0815b2896b3 2026-09-10T07:27:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-quarterly-data-up-bfc75e0710215140 2026-09-10T07:26:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/hhs-names-permanent-leaders-of-fda-drug-and-vaccine-centers-setting-the-directio-a1123af1f2b72c44 2026-09-10T07:19:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/gsk-s-shingrix-recombinant-zoster-vaccine-prefilled-syringe-presentation-approve-0b079b33cbbfd08d 2026-09-10T07:00:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/insilico-medicine-begins-phase-iii-trial-of-ai-discovered-drug-rentosertib-for-i-dadb1e5c66814ac8 2026-09-10T06:46:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/psi-cro-to-present-agile-models-for-emerging-biotech-at-oct-new-england-833dc325de531768 2026-09-10T06:46:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/seismic-pharmaceuticals-enrolls-first-patient-in-phase-3-trial-of-istaroxime-for-2b1bb847cd17d245 2026-09-10T06:46:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/genencell-scandal-revives-korea-s-kosdaq-bio-rout-as-trust-erodes-and-risk-mount-fb54093710b5acb6 2026-09-10T06:31:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/chinese-salmon-by-products-targeted-in-12-8m-biotech-deal-c8108b005d948e22 2026-09-10T05:04:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/u-s-fda-grants-priority-review-for-roche-s-enspryng-for-mogad-an-autoimmune-dise-74fecb34511c53e2 2026-09-10T05:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/stavros-nicolaou-represents-aspen-at-the-9th-annual-sadc-industrialisation-week-07118bf02b625030 2026-09-10T05:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/finnish-aq-biotech-raises-2-5m-to-scale-cancer-screening-in-china-4d00cc33ac6dddf2 2026-09-10T04:29:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/epidural-kit-correction-medical-action-industries-issues-correction-for-epidural-851483f20d7ce5fa 2026-09-10T04:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/harbour-biomed-advances-long-acting-antibody-candidate-to-phase-3-trial-bb7175ea04a5f45e 2026-09-10T03:42:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/kelun-biotech-partner-reports-positive-asthma-phase-2-trial-results-1881334f1adeeee7 2026-09-10T03:34:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/shinsa-english-translation-of-review-report-remede-system-7f6e3ec0b271b2e3 2026-09-10T03:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/kenanga-investment-bank-introduces-world-s-first-hang-seng-biotech-index-structu-2d2c97ee8f163699 2026-09-10T02:54:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/nanjing-zhongchun-biotech-rooted-in-the-ancient-capital-a-reliable-partner-in-fi-f233ef0f32fa8f8a 2026-09-10T02:36:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/aces-alumna-employs-biotech-to-create-sustainable-livestock-production-d26bebab03c30cc8 2026-09-10T02:23:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/insilico-medicine-doses-first-patient-in-genesis-ipf-3-the-world-s-first-phase-i-e40660aaa25393ab 2026-09-10T00:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gsk-filed-form-6-k-9f35af525cd09cc9 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/green-innovation-gmbh-withdrawal-of-food-additive-petition-animal-use-d90074417ad7c799 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fee-rate-for-using-a-priority-review-voucher-in-fiscal-year-2027-091f27d76fcd85b3 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-2abdf53dea0a6290 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-center-for-advancing-translational-sciences-notice-of-public-online-rou-60eabdf6f3844b70 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-devices-cardiovascular-devices-classification-of-the-mechanical-deviatio-e4a18073cc69ba43 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-devices-cardiovascular-devices-classification-of-the-temperature-regulat-1550b33975ad5831 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-devices-cardiovascular-devices-classification-of-the-extravascular-suppo-cc4f76058ba83528 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-devices-clinical-chemistry-and-clinical-toxicology-devices-classificatio-95c9753661159e4c 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-devices-ear-nose-and-throat-devices-classification-of-the-cooperative-po-053f86715c0fa357 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-devices-gastroenterology-urology-devices-classification-of-the-implanted-19651965512a4fdc 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-devices-radiology-devices-classification-of-the-vaginal-hydrogel-packing-cf0bb5f7ee0efe46 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-devices-general-hospital-and-personal-use-devices-classification-of-the-e53ed8cdd83debac 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/notice-of-supplemental-funding-medicare-rural-hospital-flexibility-program-bc670a4d8a9047aa 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/announcing-the-intent-to-award-a-single-source-supplement-to-the-senior-medicare-1c16ee7d1b83e6c7 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-caring-for-grandkids-can-help-with-brain-health-4ba5a4d5e5d8579e 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/industry-updates-from-the-field-of-stem-cell-research-and-regenerative-medicine-3a503cfbd5875d78 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/author-correction-colonoscopy-and-fecal-immunochemical-testing-versus-usual-care-a90d22f4b14aa146 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/loberamisal-for-acute-ischemic-stroke-the-lais-randomized-clinical-trial-e300cef805bc32f6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-trial-barriers-in-neurostimulation-for-pediatric-drug-resistant-epileps-8c28990dc1be1172 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/parenting-process-of-mothers-raising-low-birth-weight-infants-without-medical-te-bb80f8cd84fd4176 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/treatment-effect-discrepancy-between-pfs-and-os-in-antibody-drug-conjugate-trial-f2f94cf97134b20f 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vancomycin-rescues-sensitivity-to-isoniazid-in-clinical-isolates-of-drug-resista-39ec4e312b3f4baf 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-phase-ii-study-assessing-the-feasibility-and-clinical-efficacy-of-adaptive-imm-81f3d3cf71002166 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-retrospective-analysis-of-clinical-outcomes-following-human-deviations-from-al-60989f4665caf7ce 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/short-term-efficacy-of-tegoprazan-compared-with-esomeprazole-in-patients-with-no-52cea9f1e59c7bc3 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-function-of-angiotensin-converting-enzyme-inhibitors-in-chronic-kidney-disea-8f6ef8fb6d240f67 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/proposals-for-individually-safe-and-realistic-correction-of-antipsychotics-in-ho-05a9f8821c95edf5 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-of-a-rubric-for-assessing-essential-basic-social-skills-required-at-0a0ac5300f3dfbc9 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-evaluation-of-reduced-dose-versus-standard-dose-remdesivir-in-patients-65b51af77de0a252 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/characteristics-of-medication-errors-prevented-by-community-pharmacists-during-t-8fd3fea7f73d36c4 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmacist-secondment-implementation-of-ward-based-pharmaceutical-services-and-c-c92b42fe2d16eb49 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/continuous-intervention-by-an-antimicrobial-stewardship-pharmacist-contributes-t-046de463fe7b026c 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/identification-of-risk-factors-for-lithium-associated-renal-impairment-a-multice-5f41a254316a4f7a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluation-of-treatment-continuation-and-tolerability-using-the-urine-protein-to-7d9c0f2639c5f082 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/implementation-of-the-electronic-tracing-report-system-and-evaluation-of-its-use-71b92bcdcc397e3b 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/introduction-fcc82029050d3cfc 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/epidemiology-of-acute-kidney-injury-aki-and-sepsis-associated-aki-in-critically-b6d5977523dd237c 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-effect-of-a-telephonic-reminder-on-fasting-duration-in-children-undergoing-c-81dd7d56c74043e5 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-evaluation-of-sternomental-and-hyomental-distance-based-dynamic-airw-9b0a21c89b21e9a8 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/phantom-plethysmography-a-pulse-oximeter-artifact-caused-by-ambient-light-9d789979f52ddb2d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/thoracic-continuous-spinal-anesthesia-for-prolonged-thoracolumbar-fixation-and-k-39160d2fd342c76e 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/morphine-ketamine-combination-for-acute-trauma-analgesia-unanswered-questions-be-a688b64ea7fdcefb 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/therapeutic-responses-and-6-month-clinical-outcomes-in-sarcoidosis-a-longitudina-1dfb2b94343d3422 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-evaluation-of-patient-performed-cleaning-methods-on-the-integrity-of-1841900d0724de48 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-profile-risk-factors-and-treatment-outcomes-of-diabetic-foot-ulcers-a-p-4373b3d863bde44d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-between-brain-natriuretic-peptide-and-intradialytic-hypotension-in-h-a365fbb4949ebe9d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/left-atrial-appendage-occlusion-vs-oral-anticoagulants-current-evidence-and-deba-5f809c5eb8e4f23b 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/electrotherapy-in-pediatric-rehabilitation-a-structured-narrative-review-of-clin-d2236a91b304d8e6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cbct-based-anatomical-assessment-of-lingual-bone-availability-relevant-to-the-me-4d89c9009e1b662a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/personality-and-coming-to-terms-with-cancer-a-cross-sectional-study-of-five-fact-0ead1686b1643e4b 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/circulating-interleukin-17-across-airway-disease-phenotypes-a-single-center-obse-2fdf11ea2437bca3 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/impact-of-age-on-success-of-3d-printed-cranial-remolding-orthoses-for-deformatio-9aa46e3dc891e64d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/exercise-induced-bronchoconstriction-in-school-aged-children-born-very-preterm-p-ae54f67e30689774 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/multilevel-mechanisms-and-clinical-efficacy-of-psilocybin-in-depression-treatmen-c152eb701a32b92c 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/user-centered-design-approach-to-dynamic-clinical-decision-support-in-primary-pr-311b856abb73970d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comment-on-huang-et-al-accuracy-and-agreement-of-a-45-mg-versus-a-75-mg-13c-urea-c3adf5d3af9f3d93 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-and-new-treatments-in-pediatric-brain-tumors-a7ae81bda7df0329 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-mitochondrial-support-to-mitohormetic-readiness-a-micronutrient-centric-ext-f324d9fbecf27cf9 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/impact-of-ethanol-sclerotherapy-on-pelvic-pain-and-quality-of-life-in-patients-w-272a8ec4a97d9120 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparison-of-live-birth-rates-between-calorie-restricted-diet-and-metformin-pri-e6f52d6cd1926e2d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/shunt-pathophysiological-mechanisms-and-clinical-implications-of-ineffective-cir-3955f02cf56865e4 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hypericin-and-hyperforin-from-st-john-s-wort-are-potent-intestinal-ugt-inhibitor-10d289e1efb49df5 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/foxc1-drives-lung-cancer-metastasis-and-functions-as-a-target-for-ai-enabled-ant-1defa9cda85e5e4f 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-a-negative-trial-timing-molecular-residual-disease-and-antibody-biology-i-bb05374d7dd1fb5e 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/acupuncture-for-chronic-tinnitus-study-protocol-for-a-clinical-trial-with-audito-8863c954452a2b82 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/control-effect-of-dual-mechanism-myopia-control-lenses-on-myopia-in-children-and-7da4cb5525ea95aa 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-warrant-in-medical-llm-evaluation-459f9d52d16df761 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/presidential-inaugural-address-2026-expanding-computer-based-testing-strengtheni-15fe341fe4ecbd79 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/artificial-intelligence-and-the-right-to-a-fair-trial-in-the-context-of-ensuring-b0afc141737b48ad 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/larval-density-development-and-distribution-of-costelytra-giveni-in-a-first-year-dfa5c9918d6a640a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-contribution-of-instagram-influencers-to-drug-literacy-a-digital-communicati-9b940a97b351f178 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/one-year-comparison-of-three-maintenance-doses-of-vitamin-d3-600-1000-and-2000-i-7d271c298d361625 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-drug-interactions-and-pharmacological-complexity-as-prognostic-determinants-36411921172495c4 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/when-thyrotropin-meets-growth-hormone-clinical-challenges-of-a-mixed-gh-tsh-secr-582838b0171f14b7 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/indications-of-a-dependent-invention-for-the-use-of-which-a-compulsory-license-m-090bbb27c034b7e9 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrating-clinical-and-cephalometric-assessment-a-comparative-review-b29ec57ce2d2f40a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/photodynamic-therapy-of-onychomycosis-modern-photosensitizers-and-clinical-effic-64ce2376748684d7 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/procedural-and-clinical-outcomes-of-second-generation-robotic-assisted-versus-ma-2ff0a102943ed8cd 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cardiac-troponin-in-pediatric-cardiology-toward-standardized-interpretive-framew-c21aedff40641d2d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-comparative-evaluation-of-p-tau217-stability-in-serum-and-plasma-using-two-val-e3b099e3c956cdd5 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/din-spec-91532-a-process-oriented-framework-for-quality-assurance-in-clinical-ma-af7479e9fd68713e 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-factors-related-to-cardiac-conduction-disturbance-in-patients-with-wild-1960f220eca28d40 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-impact-of-hospital-associated-disability-in-patients-with-acute-decompe-5990a34ce35f7358 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/high-intensity-statins-and-the-post-discharge-clinical-outcomes-at-1-year-after-6772e5c513209aca 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/endomyocardial-biopsy-and-clinical-outcomes-in-acute-myocarditis-multicenter-coh-ad26290eeb8a3c67 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/detection-of-crystalline-ibuprofen-components-in-ibuprofen-loaded-sba-15-mesopor-7138db2e1588d3b6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluation-of-water-related-lt-i-gt-t-lt-i-gt-lt-sub-gt-2-lt-sub-gt-relaxation-b-0d37b85783605e80 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/exploring-the-therapeutic-impact-of-targeting-brk-in-epithelial-derived-cancer-c-de1a23859be6977e 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/realgar-transforming-solution-triggers-ferroptosis-associated-death-in-nb4-leuke-a1c5b8ee91dfa235 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/critical-medicines-lists-in-japan-and-the-european-union-insights-into-supply-re-b3c63434f9bb8e7d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hydrophobic-compounds-in-the-lt-i-gt-paeonia-suffruticosa-lt-i-gt-root-cortex-re-fcc2875b79003b62 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/153abr-clinical-procedure-applications-d0e4148b0fd3773b 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/erratum-safety-tolerability-and-antitumor-activity-of-zipalertinib-among-patient-9348373953769dba 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/erratum-efficacy-and-safety-of-anselamimab-in-immunoglobulin-light-chain-amyloid-94141529a1094132 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/therapy-for-stage-iv-non-small-cell-lung-cancer-with-driver-alterations-asco-liv-959d85f1292c4974 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/reply-to-role-of-risk-reducing-bilateral-mastectomy-in-i-brca1-i-and-i-brca2-i-p-775da0d78d9dcbd0 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/reply-to-olaparib-in-metastatic-breast-cancer-the-impact-of-prior-cyclin-depende-d2c1227aecb440ba 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/intismeran-autogene-plus-pembrolizumab-versus-pembrolizumab-alone-in-high-risk-r-d4126ebab8f61724 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/he-was-always-there-f0fcbcf89c659ca0 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/olaparib-in-metastatic-breast-cancer-the-impact-of-prior-cyclin-dependent-kinase-df42a6f811bc75a6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/combi-i-long-term-overall-survival-with-spartalizumab-plus-dabrafenib-and-tramet-952659f5b36f2fcf 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/role-of-risk-reducing-bilateral-mastectomy-in-i-brca1-i-and-i-brca2-i-pathogenic-82dafac178eac60b 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/developing-a-histology-based-artificial-intelligence-biomarker-to-predict-adjuva-7a52e5237fb6ed1f 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/should-artificial-intelligence-direct-systemic-therapy-decisions-in-pancreatic-c-c4a0a33b2312faed 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sustaining-high-reliability-amid-artificial-intelligence-adoption-in-oncology-593d81fb37071e65 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/oncology-drug-development-challenges-of-increasingly-available-therapies-ca545af2dd113f6f 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/impact-of-tumor-genomic-profile-on-adjuvant-chemotherapy-efficacy-in-resected-pa-3334b8a840da9cbe 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-and-validation-of-a-computational-histology-artificial-intelligence-ea25f506da3e0dd0 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/phase-ii-clinical-study-of-adebrelimab-and-bevacizumab-combined-with-cisplatin-c-c6e26ef3d70cbaea 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/magrolimab-plus-azacitidine-versus-placebo-plus-azacitidine-in-patients-with-unt-f50f60a602c26239 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/spotlighting-rising-researcher-lucas-attia-from-drug-nanoparticle-engineering-to-80d678c9fb2b6243 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-changes-in-cardiovascular-measures-following-speed-agility-and-quick-7d38e12c591165cb 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/performance-of-artificial-intelligence-chatbots-in-restorative-dentistry-a-compa-9b191fa00532fd63 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sterile-neutrophilic-pseudomembranous-conjunctivitis-associated-with-tisotumab-v-d38695f0b78e7a1b 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparison-of-two-tooth-whitening-treatments-a-randomized-split-mouth-clinical-t-c0c6e1e2d0ef8771 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-observation-on-four-finger-pushing-manipulation-combined-with-acupunctu-a2814a38ddb8384a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-significance-of-inter-assay-discrepancies-and-regression-derived-correc-3228176469d0ff16 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-clinical-prediction-model-for-self-harm-after-adolescent-traumatic-brain-injur-e24ad5ae8d0cc3dd 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vancomycin-rescues-sensitivity-to-isoniazid-in-clinical-isolates-of-drug-resista-e8b7cbd1c4a03064 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/when-tests-don-t-fit-the-rules-regulatory-challenges-for-agnostic-metagenomic-ne-331f129d805b783b 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/indications-techniques-and-complications-associated-with-pterygoid-implants-a-sy-83a100367b3cf247 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/diagnostic-yield-of-brain-mri-in-pediatric-short-stature-hypothalamic-pituitary-74fd0b47c4324c38 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-development-and-initial-validation-of-the-perinatal-intrusions-interpretatio-e0c5c555f7035197 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-influence-of-social-media-on-users-intention-to-participate-in-clinical-tria-e5c75968b8839648 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/price-gouging-in-the-b2b-pharmaceutical-market-a-systematic-review-of-unethical-c525db114cfe942a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hypnosis-for-postoperative-pain-management-following-colectomies-a-single-center-2399ea4259a39d8e 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/heart-failure-among-people-with-hiv-prescription-of-guideline-directed-medical-t-13740b1e548b1bb9 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-user-centric-patient-educational-intervention-in-clinical-practice-helping-wom-65d17fa745ccd8e6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/autophagy-activation-in-granulosa-cells-as-a-mechanism-of-astaxanthin-action-evi-837d5d6cedcc31a1 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/silk-sericin-fibroin-composite-drug-delivery-systems-for-lung-cancer-mechanistic-8a8fa26cb15838c7 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effects-of-guided-imagery-supported-psychoeducation-on-self-esteem-perceived-str-081b38975cbead8e 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/applying-natural-language-processing-to-address-healthcare-bias-using-care-sd-to-ef4b247727690352 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/when-fear-became-the-barrier-to-care-lessons-of-a-clinical-rapid-response-during-40975bffd5c0cbd9 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-virtual-reality-cardiopulmonary-bypass-simulator-versus-conventional-halstedia-ac64a873d60ef83c 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-lipid-ingestion-is-sensed-the-mechanisms-underlying-intestinal-hormone-secre-22afd06b3217a312 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/differential-detection-of-tau-aggregation-species-using-a-small-molecule-probe-f-d66e0f055a747884 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pre-treatment-prediction-of-ebv-dna-status-in-nasopharyngeal-carcinoma-using-ce-a68cbee4efda910c 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrating-artificial-intelligence-and-quantum-chemistry-for-sustainable-pharma-2d6f3ac18e807696 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/author-correction-colonoscopy-and-fecal-immunochemical-testing-versus-usual-care-55d47fa59cf1d06d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/aptamer-functionalized-dna-frameworks-as-targeted-drug-buffers-for-concentration-80b9dd9403406b46 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/an-explainable-ai-framework-for-early-mental-health-screening-and-clinical-decis-d1bcabc444546af5 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/trust-and-the-reliability-of-ai-algorithms-for-clinical-decision-making-support-9e4b561742c5eac6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/potenzial-und-herausforderungen-von-large-language-models-in-der-klinischen-ents-aab5af7bbb512e77 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-deubiquitinating-enzyme-regulatory-network-in-malignant-progression-of-breas-1ae6f24cf43a9983 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-laboratory-and-radiological-factors-associated-with-posterior-reversibl-ada55e4fd84835f5 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agreement-between-artificial-intelligence-and-periodontists-in-the-detection-of-19457d539500c908 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/preserving-beta-cell-function-in-children-and-adolescents-with-newly-diagnosed-s-57b94481282b6072 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07813208-ph-all-in-chinese-children-diagnosis-treatment-and-survival-eb09a4a0ca15599d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07812636-tirzepatide-and-levonorgestrel-iud-therapy-for-ein-and-early-stage-e-62fa618027a35796 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07812402-the-effect-of-factors-affecting-bone-mineral-density-measurement-res-2973f03482cf3684 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07812142-retrospective-analysis-of-the-second-year-of-safety-surveillance-of-2d8c760820377312 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07811817-the-outcomes-of-sympathetic-cardiac-denervation-on-postoperative-atr-6898ffb279287097 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07807579-impact-of-dexmedetomidine-versus-propofol-on-intracranial-pressure-i-3ebfbb09eb810a2c 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07802639-treatment-for-asymmetric-crying-facies-6a5482072b6db189 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07796880-neoadjuvant-culmerciclib-combined-with-endocrine-therapy-for-hormone-236a6ff0dd7aaab3 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07757334-trauma-focused-group-therapy-for-adults-with-trauma-related-symptoms-938497b4eae7f668 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07755800-impact-of-an-arginine-containing-toothpaste-on-the-subgingival-micro-a66ba8f161165838 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07619547-longitudinal-immunophenotyping-of-patients-with-inflammatory-bowel-d-3a796411228812d2 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07619014-comparison-of-the-effectiveness-of-miswak-and-manual-toothbrush-in-r-61752a5ba9670351 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07510737-the-effect-of-cross-training-on-clinical-and-functional-outcomes-in-7510d95205e24ef6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07490925-transpulmonary-pressure-guided-mechanical-ventilation-strategy-in-ri-67a89935b4d97fdb 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07403487-phase-ii-trial-of-rc1416-injection-in-asthma-3a70f1e833dd11d1 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07391774-testing-whether-hormone-therapy-with-ribociclib-is-as-effective-as-c-950c4ddcb9c97097 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07346768-evaluation-of-anterior-neck-ultrasound-in-predicting-difficult-airwa-e45c6f540528963b 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07301333-a-study-of-single-and-multiple-doses-of-hrs-6257-in-healthy-subjects-b397d0795f6d989a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07252245-pre-hospital-triage-of-patients-at-intermediate-and-high-risk-for-ac-80a6b5fc1f6fe45d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07195734-testing-the-addition-of-chemotherapy-or-chemo-immunotherapy-to-the-u-eaef4d5ec3a3e699 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07000253-timing-of-comprehensive-local-treatment-after-first-line-systemic-th-342d10d4c9ccc441 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06991751-a-natural-history-of-cardiometabolic-disease-among-us-bhutanese-deve-74080274b3baf1da 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06834984-ritual-synbiotic-a-dietary-supplement-designed-to-impact-gastrointes-812e09906b02af8f 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06728592-emergency-stroke-unit-for-acute-cerebrovascular-events-a-prospective-ce25f2838db0d108 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06687369-a-study-to-compare-pharmacokinetics-efficacy-safety-and-immunogenici-f27ee34c79201243 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06646627-clinical-trial-of-autologous-b7-h3-car-t-cells-in-reoccurent-platinu-64da8d624df467f8 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06595940-genetic-analysis-of-uncommon-disease-presentations-in-non-us-populat-9a7defcdd77feca2 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06485622-outcome-and-improvement-of-different-treatment-in-arteriosclerosis-o-9e6f55f052856edc 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06473857-design-implementation-and-evaluation-of-an-intervention-within-video-e815a59dea39ec4a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06360822-increasing-equity-in-lung-cancer-screening-b4a214aae70631f2 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06345079-cessation-of-somatostatin-analogues-after-prrt-in-mid-hind-gut-and-p-ed61837c12c16b51 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06339177-hemophagocytic-lymphohistiocytosis-hlh-evaluation-and-research-of-cl-98ebc57a25bf0463 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06277401-exercise-in-patients-with-hypermobile-joints-and-knee-pain-b27705bc9cf79ce5 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06040125-debunking-the-frailty-sarcopenia-adt-axis-in-metastatic-prostate-can-128757a54a83f5c8 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06024746-a-study-to-determine-the-efficacy-and-safety-of-finerenone-and-sglt2-da7f590809573fe2 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06014827-biologically-guided-radiation-therapy-bgrt-and-stereotactic-body-rad-d9c90c38d3384a71 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05960461-families-moving-forward-fmf-connect-pro-for-mental-health-providers-c10658528e77ed2e 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05726526-ckd-specific-telemonitoring-platform-to-minimize-adverse-outcomes-in-6ed1dd4b247198a9 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05713799-trial-of-the-combination-of-alpha-lipoic-acid-and-mirabegron-in-wome-58ca62d5ec6a8459 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05692687-a-post-market-clinical-study-to-evaluate-the-safety-and-performance-d750517fead1c294 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05564390-myelomatch-a-screening-study-to-assign-people-with-myeloid-cancer-to-24330c5ca77ac0cb 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05413343-clinical-study-on-monitoring-the-plasma-concentration-of-ceftazidime-1798b3f69bd38b0f 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05027386-apatinib-mesylate-combined-with-it-regimen-for-the-treatment-of-recu-f8c8487f9f0e5b11 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04864054-gpc3-targeted-t-cell-therapy-ect204-in-adults-with-advanced-hcc-4ac96ef3c3032db6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04288869-change-in-brain-perfusion-during-induction-of-general-anesthesia-0597049227a260ac 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03964532-talave-induction-talazoparib-followed-by-combination-of-talazoparib-ef82b804574ba6bf 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03952637-a-phase-1-2-study-of-intravenous-gene-transfer-with-an-aav9-vector-e-a43bede94f74abe6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03424005-a-study-evaluating-the-efficacy-and-safety-of-multiple-treatment-com-7cf230def61e35fe 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03077061-peri-implantitis-reconstructive-surgical-therapy-8ced217a0ad67979 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01471834-verification-of-the-efficacy-and-safety-of-the-barostim-neo-system-i-92140cd6f7208e5a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01426165-effect-of-magnesium-sulfate-infusion-rate-on-magnesium-retention-in-d3fa07dc21a48b44 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01087320-genome-medical-sequencing-for-gene-discovery-3e5a241c98c3dee8 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01029873-quilt-2-008-study-of-alt-801-with-cisplatin-in-patients-with-metasta-aa0122aaeeb4afc4 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hanmi-pharmaceutical-target-price-raised-to-650-000-as-roche-deal-value-reflecte-7b981f6d3cd04d61 2026-09-09T23:35:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-rare-after-aspire-miss-and-genglycos-win-has-valuation-3ffec4f293a82118 2026-09-09T23:28:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/portage-biotech-alp-financials-2026-income-statement-and-balance-sheet-alp-a532834d0e460662 2026-09-09T23:15:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-company-expanding-adding-jobs-in-hauppauge-d80f5da0a5cd0868 2026-09-09T23:04:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/research-national-commission-into-the-regulation-of-ai-in-healthcare-recommendat-ebbddaf59e9d3532 2026-09-09T23:01:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/rebuilding-mexico-s-pharmaceutical-supply-chain-3e5a86b66630a924 2026-09-09T22:42:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/potential-pill-for-peanut-milk-egg-allergies-enters-phase-3-trial-9b77f26228e19997 2026-09-09T22:35:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/louisiana-ag-takes-fda-and-pharmaceutical-companies-to-court-over-abortion-pills-1ec522bb7e31fbae 2026-09-09T21:53:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/louisiana-ag-takes-fda-and-pharmaceutical-companies-to-court-over-abortion-pills-2bbc103d0de45256 2026-09-09T21:46:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/biden-era-by-mail-abortion-pills-can-t-be-halted-despite-safety-data-gap-appeals-e16ccb2f49768bd5 2026-09-09T21:39:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/hhs-names-four-senior-fda-officials-in-leadership-reorganization-54cf11cc363bef01 2026-09-09T21:34:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/generation-park-is-creating-a-national-pharmaceutical-hub-in-houston-bba29ce5588183be 2026-09-09T21:10:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/meet-annalina-che-the-scientist-behind-biotech-start-up-darkfin-labs-c8d101f77eaedcec 2026-09-09T20:08:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/placebos-in-cancer-clinical-trials-what-patients-need-to-know-242a8672b78243ea 2026-09-09T20:06:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/seismic-pharmaceuticals-commences-global-phase-3-trial-of-istaroxime-in-patients-08ecec56915041b8 2026-09-09T20:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/shareholders-back-every-proposal-at-purple-biotech-ppbt-2026-meeting-8cc35989e741aa3e 2026-09-09T20:02:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/technology-transfer-success-drivers-and-obstacles-explained-f93565e6205cc9ff 2026-09-09T19:36:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/kelun-biotech-s-twice-yearly-asthma-candidate-skb378-advances-into-phase-iii-6e6421b7f6e08843 2026-09-09T18:54:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/kelun-biotech-s-twice-yearly-asthma-candidate-skb378-advances-into-phase-iii-c198555d2578e70f 2026-09-09T18:35:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-appeals-court-skeptical-of-bid-to-curtail-abortion-pill-access-6e050300f86774f7 2026-09-09T18:31:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/wall-street-slashes-dyne-therapeutics-targets-after-novartis-dm1-trial-failure-f71e254e2955835d 2026-09-09T18:24:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nueva-convocatoria-para-realizar-practicas-preprofesionales-0a0fa80b13f1b170 2026-09-09T18:20:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/u-s-and-tunisian-officials-break-ground-on-renovation-of-ministry-of-health-phar-ba2e86b24a145546 2026-09-09T18:19:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/leukemia-drug-data-suggested-a-different-way-to-treat-diabetes-a-new-biotech-wil-951cf12440ea5591 2026-09-09T17:57:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/cualtos-opens-registration-for-the-bachelor-s-degree-in-pharmaceutical-chemistry-cd37687b38cd07c5 2026-09-09T17:22:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/mbrx-stock-drops-25-as-moleculin-biotech-s-interim-cancer-trial-data-falls-short-d8f025f87aa6b36f 2026-09-09T16:54:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/appeals-court-skeptical-that-louisiana-can-sue-fda-over-mifepristone-being-maile-a16892c426e35ef1 2026-09-09T16:51:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/news-today-satya-niketan-collapse-a-wake-up-call-to-act-but-why-wait-for-tragedi-9e4d71030a910565 2026-09-09T16:37:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharma-s-r-d-commercial-approach-shifts-amid-global-policy-evolution-65d9e6dd72fa76dc 2026-09-09T16:35:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-fluidics-releases-upgraded-degasi-inline-degasser-range-147cc76d79d3987c 2026-09-09T16:32:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-firm-uses-space-to-help-cells-regenerate-bodily-structures-12b843a0aabf818f 2026-09-09T16:21:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-firm-uses-space-to-help-cells-regenerate-bodily-structures-75ef1e4053d689b2 2026-09-09T16:21:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/alpha-genesis-backs-biotech-startups-with-50m-agi-ventures-fund-99f88ef051673c6f 2026-09-09T16:19:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/eu-court-adviser-backs-challenge-to-pharmaceutical-wastewater-charges-f5177be301b558f1 2026-09-09T16:15:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/kura-spins-diabetes-work-into-a-lilly-backed-biotech-startup-ee94fc840173114d 2026-09-09T16:14:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-stocks-to-consider-september-9th-b898d2190cfcaabb 2026-09-09T16:07:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/ima-group-to-showcase-all-in-one-solutions-at-cphi-milan-8f37948273925931 2026-09-09T16:06:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/faq-inside-the-latest-mfn-deals-signed-by-nine-drugmakers-03b08aa8809af0e0 2026-09-09T16:03:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/one-state-s-abortion-ruling-could-affect-all-50-0b0a9758c1ef7862 2026-09-09T16:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/four-biotech-stories-heating-up-right-now-f51da81af50695d6 2026-09-09T15:55:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-fills-four-senior-roles-including-top-officials-for-drugs-vaccines-and-tobac-12068fd76e56966c 2026-09-09T15:55:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-promoting-visiting-impact-assessment-8e5c43f577238ed7 2026-09-09T15:46:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/veraxa-biotech-designates-raju-willener-as-cfo-801ec29de9a56a5a 2026-09-09T15:46:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-medical-device-licensing-regime-impact-assessment-27313ede92bd836d 2026-09-09T15:46:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-050bf26e4894b2ca 2026-09-09T15:46:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-mhra-reforms-impact-assessments-d4da977182c6d068 2026-09-09T15:46:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-changes-to-pharmacy-appeals-process-impact-assessment-a5f9700a9414e0ed 2026-09-09T15:46:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-changes-to-section-75-of-nhs-act-2006-impact-assessment-5f9809bc31c7871f 2026-09-09T15:46:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-patient-safety-measures-impact-assessments-092abe2dadcce996 2026-09-09T15:46:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-role-and-functions-of-the-restructured-dhsc-fact-sheet-89c454d704f2bab3 2026-09-09T15:46:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-structural-measures-to-icbs-and-foundation-trusts-impact-assessments-7a34cf0996abe91d 2026-09-09T15:46:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-providers-fact-sheet-ad8fa072da7a9f6e 2026-09-09T15:46:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-icbs-as-strategic-commissioners-fact-sheet-6de16d25a204e1ef 2026-09-09T15:46:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-abolishing-nhs-england-impact-assessment-00de0de68dc58510 2026-09-09T15:45:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-icbs-as-strategic-commissioners-equality-impact-assessment-61dc9515198e3cd9 2026-09-09T15:45:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-impact-assessments-summary-744fa7c4f88e3806 2026-09-09T15:45:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-abolishing-nhs-england-equality-impact-assessment-a15632314deab107 2026-09-09T15:45:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-equality-impact-assessments-summary-8eeb40343ce210f9 2026-09-09T15:45:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/wall-street-weighs-impact-on-dyn-stock-post-novartis-phase-3-failure-rbc-says-th-ab7d5395de69c328 2026-09-09T15:41:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-promoting-visiting-equality-impact-assessment-33c1a8f7b32a87b9 2026-09-09T15:40:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-medicines-and-medical-devices-regulatory-reforms-fact-sheet-7269b5ea8e00e2df 2026-09-09T15:40:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-s-del-desiran-misses-primary-endpoint-in-phase-3-dm1-trial-99ce4a179960b851 2026-09-09T15:31:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-suspends-food-licenses-of-railway-catering-supplier-20-eateries-1bf82f8f784bec1c 2026-09-09T15:28:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-the-biggest-ndc-12-risk-sits-in-the-handoffs-3d5e69a55011a8ea 2026-09-09T15:23:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/decision-medical-devices-given-exceptional-use-authorisations-bea04f575ed28a14 2026-09-09T15:08:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/federal-appeals-court-hears-baseless-challenge-to-the-abortion-pill-mifepristone-940486b7c14cf63f 2026-09-09T14:56:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/beeline-medicines-19dae1080a3df20c 2026-09-09T14:52:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/this-biotech-stock-crashed-28-today-after-announcing-second-reverse-share-split-b0b395313df17574 2026-09-09T14:46:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-account-teams-call-claimguardrx-their-smartest-teammate-24ca28a696436c27 2026-09-09T14:24:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-proprietary-llm-behind-claimguardrx-s-detect-and-respond-engine-756b5ec033050dc5 2026-09-09T14:24:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/kura-creates-lilly-backed-spinout-armed-with-50m-to-advance-next-gen-diabetes-th-f97b4a180f77d74c 2026-09-09T14:20:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/macrogenics-inexpensive-adc-tce-biotech-with-multiple-catalysts-ahead-nasdaq-mgn-3992c5961012659d 2026-09-09T14:15:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/ideaya-biosciences-doses-first-patient-in-phase-3-trial-d00198a17e0c725f 2026-09-09T14:10:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/leerink-partners-initiates-coverage-on-teva-pharmaceutical-industries-nyse-teva-b4f76e98ec172cbd 2026-09-09T14:08:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-transition-to-home-why-confidence-is-critical-to-patient-success-f53fe705f45b7442 2026-09-09T13:58:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/matica-bio-bondwell-partner-on-texas-biotech-d0f4351f2a06e4f3 2026-09-09T13:56:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/trump-order-directs-federal-push-on-psychedelic-drug-research-and-review-7a02808d8f427079 2026-09-09T13:48:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/acrp-launches-2026-27-scholarship-and-grant-application-season-4a9b54371cfd920f 2026-09-09T13:45:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/orexin-discoverers-awarded-prestigious-lasker-award-0889c17faef35301 2026-09-09T13:43:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/luma-locks-down-15-year-410m-fund-for-life-science-investments-2229e6c1a7656df9 2026-09-09T13:43:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/field-safety-notices-31-august-to-4-september-2026-4fbb5b1daae2c350 2026-09-09T13:41:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/new-52-week-topline-open-label-data-from-phase-3-comp005-trial-the-power-of-anot-3ee7227f8517bd81 2026-09-09T13:38:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/nutriband-ceo-gareth-sheridan-to-attend-inaugural-nasdaq-lab-biotech-summit-1307e17da858ae68 2026-09-09T13:31:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tyra-rolls-toward-pivotal-cancer-study-even-as-stock-deflates-06453e4e0f97fa39 2026-09-09T13:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/five-years-at-bio-mexico-gaining-ground-in-global-biotech-ec0a6f6068da0a75 2026-09-09T13:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/matica-biotechnology-and-bondwell-technologies-collaborate-to-advance-texas-biot-cf7873ac652d7f27 2026-09-09T13:09:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/guggenheim-reveals-top-biotech-stock-after-positive-clinical-trial-data-c106ca309e8a6793 2026-09-09T13:09:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/ocugen-doses-first-patient-in-phase-3-ga-gene-therapy-trial-32970696c462f25b 2026-09-09T13:06:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/decision-human-medicines-register-of-electronic-export-certificates-734f447a25d821db 2026-09-09T13:03:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/viral-haemorrhagic-fever-acdp-algorithm-and-guidance-on-management-of-patients-a442005e4b179daf 2026-09-09T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/impact-biotech-announces-completion-of-treatment-in-phase-3-enlighted-trial-of-p-39acc0eee159b7fc 2026-09-09T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/suddenly-this-summer-biotech-breaks-open-with-drug-approvals-ipos-will-it-last-25bef14c1bde5876 2026-09-09T12:57:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/decision-suspended-and-revoked-licences-and-registrations-for-manufacturers-and-258d162076f199f0 2026-09-09T12:42:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/nordic-biotech-ceos-reveal-secret-to-major-funding-and-pharma-deals-a3efea1f52140818 2026-09-09T12:37:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/don-t-ignore-the-insider-selling-in-biomarin-pharmaceutical-c392d2b0a526d595 2026-09-09T12:36:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/nitrosamines-from-detection-to-understanding-c0e645b8909bb3aa 2026-09-09T12:36:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/anmat-dispuso-la-baja-de-habilitacion-de-la-firma-rehue-s-a-y-prohibio-sus-produ-95c8696ba780c6c0 2026-09-09T12:32:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmasource-podcast-how-exoz-is-running-a-10-cdmo-rfp-for-cdmo-selection-3a007b19e8cf1ab3 2026-09-09T12:31:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-paid-pilot-will-test-trinity-biotech-cooling-fluids-in-ai-data-centers-7fd633709f73fc8c 2026-09-09T12:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/over-1-5-billion-to-help-nhs-withstand-year-round-pressure-cbf84c3935b064e9 2026-09-09T12:26:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-narcolepsy-drug-showed-median-reductions-of-up-to-88-8-in-sudden-muscle-loss-a-0ff7d04798652a97 2026-09-09T12:24:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-35523ec4937619f8 2026-09-09T12:13:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/atmospheric-nox-may-contribute-to-ndsri-formation-study-shows-717a069d3a62c417 2026-09-09T12:12:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-back-to-back-phase-3-failures-for-pelacarsen-and-del-desiran-send-share-2bac2be2f578a969 2026-09-09T12:10:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/world-health-expo-to-showcase-trillion-dollar-growth-across-pharma-biotech-longe-6803da287ace71b1 2026-09-09T12:07:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-may-2e45bd7b86003737 2026-09-09T12:06:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-apri-b7f6f80136a72c29 2026-09-09T12:06:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-marc-a9688d88c3a30590 2026-09-09T12:05:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-febr-df1ca0002f7ddc6b 2026-09-09T12:05:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-june-a0324311fd4d4714 2026-09-09T12:05:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-july-e4a658a591d9a33e 2026-09-09T12:04:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-augu-e29136a0758c031f 2026-09-09T12:04:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-sept-dd9b886471b7e27e 2026-09-09T12:04:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-octo-63ff575955c0b169 2026-09-09T12:04:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-janu-6665f6d4d545e2ad 2026-09-09T12:03:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-pays-50m-milestone-as-mrt-6160-enters-phase-2-for-sjogren-s-disease-168b743c3496ab83 2026-09-09T12:03:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-dece-b514e806327cec75 2026-09-09T12:03:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-nove-9bc61a228a7791a8 2026-09-09T12:03:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-octo-b016e524e13c6091 2026-09-09T12:02:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-sept-700ae1d4dc61471f 2026-09-09T12:01:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/rezera-announces-ruvonoflast-met-its-primary-inflammation-551bfbb3756d9d66 2026-09-09T12:01:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-3-f66515bf33b9f262 2026-09-09T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/three-chugai-researchers-behind-the-discovery-of-hemlibra-for-hemophilia-a-recei-818232e0bd38792c 2026-09-09T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/veradius-unity-and-bv-pulsera-mobile-c-arm-system-9in-and-12in-versions-0cb1d977b3032a6a 2026-09-09T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/philips-ingenia-achieva-and-intera-mr-systems-b7e6009e9e3fb961 2026-09-09T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nodthera-inc-changes-name-to-rezera-inc-and-announces-ruvonoflast-phase-3-develo-e4a7e3b646456dbf 2026-09-09T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/court-of-appeals-hears-oral-arguments-in-louisiana-abortion-pill-lawsuit-50fa9321f5302288 2026-09-09T11:50:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/dyne-therapeutics-remains-a-buy-even-as-novartis-trial-failure-hits-dm1-class-na-eccaccfab2da6505 2026-09-09T11:45:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/ganesh-chaturthi-2026-mumbai-s-12-000-ganesh-mandals-under-fda-scanner-over-pras-be7950d397f186f7 2026-09-09T11:27:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/mirum-pharmaceuticals-hires-lmh-strategic-solutions-284e103ab1270aa8 2026-09-09T11:24:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/decision-advertising-investigations-august-2026-0b95edb50287d7e6 2026-09-09T11:23:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/article-141-1-procedure-quarter-based-selective-dry-cow-therapy-dc21887708f5021b 2026-09-09T11:22:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/141-1-7a946e163c61ea87 2026-09-09T11:20:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/meningococcal-disease-guidance-data-and-analysis-cf4d903cf180377a 2026-09-09T11:16:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/adult-social-care-client-level-data-england-quarterly-update-to-june-2027-bab1705385315cda 2026-09-09T11:15:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/adult-social-care-client-level-data-england-quarterly-update-to-september-2026-404dfd4156db3fd3 2026-09-09T11:15:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/opus-genetics-announces-positive-low-dose-cohort-1-data-from-phase-1-2-clinical-9da1ba6971e41fb4 2026-09-09T11:06:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/kane-biotech-to-host-commercial-update-webcast-on-september-16-9a8886880a182539 2026-09-09T11:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/111-patient-eye-pain-trial-planned-by-okyo-pharma-nasdaq-okyo-84beab271f892e82 2026-09-09T11:00:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/algorithmic-tool-may-improve-screening-of-patients-for-an-alzheimer-s-clinical-t-562efba4ceb9605d 2026-09-09T11:00:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-is-still-reviewing-rezolute-s-experimental-drug-no-timeline-is-set-cf406d8464aac8e4 2026-09-09T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/beeline-flies-into-ph-3-as-oral-lupus-drug-soars-past-placebo-303874c2252c60b3 2026-09-09T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/exclusive-cancer-biotech-twostep-gets-62-5m-to-take-twist-on-adcs-into-clinic-817e254766ff52c2 2026-09-09T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/matica-biotechnology-and-bondwell-technologies-collaborate-to-advance-texas-biot-0849105330920f96 2026-09-09T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/schrodinger-births-new-immunology-and-inflammation-biotech-tectora-therapeutics-3c2ecfcd5bb63fb8 2026-09-09T10:58:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/solstice-rises-with-225m-series-a-to-advance-next-gen-ctla-4-immunotherapy-into-398cbf270d73588b 2026-09-09T10:58:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-manufacturing-questions-facing-chinese-biotech-cf50d2874a8599be 2026-09-09T10:56:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/tukaram-mundhe-s-food-order-for-festivals-what-maharashtra-fda-commissioner-said-3dd813ddcd70dbc5 2026-09-09T10:54:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/moonwalk-banks-70m-to-progress-sirna-therapy-for-obesity-de269d2e1175ff14 2026-09-09T10:50:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/unparalleled-opportunity-sandoz-embarks-on-ambitious-biosimilar-growth-strategy-676c4323204a4fcf 2026-09-09T10:49:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/mannkind-and-rose-pharma-inc-enter-licensing-and-collaboration-agreement-to-deve-9e7da1cb20ba16a8 2026-09-09T10:46:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-rapid-acting-short-duration-inhaled-treatment-is-being-developed-for-weight-ma-e383768e6e897a31 2026-09-09T10:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/compass-pathways-new-52-week-topline-open-label-data-from-phase-3-comp005-trial-6da5752584aa882a 2026-09-09T10:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/guidance-medicines-that-you-cannot-export-from-the-uk-or-hoard-6902f574353aeb80 2026-09-09T10:28:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-makes-pharmaceutical-speaker-programs-illegal-f87d152b9ae8d979 2026-09-09T10:10:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-global-eye-cancer-trial-has-dosed-its-first-patient-529d4d314833481c 2026-09-09T10:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biden-era-abortion-by-mail-rules-face-key-test-at-appeals-court-hearing-0cd9e746f1b92012 2026-09-09T10:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nafdac-and-nhrec-announce-new-dates-for-mandatory-stakeholders-training-on-clini-c75adb4ff13bd3af 2026-09-09T09:53:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-among-independent-f32c88a42723b612 2026-09-09T09:50:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/neuromuscular-drug-from-novartis-fails-in-key-study-adding-to-pressure-on-compan-7599cd1f8178910a 2026-09-09T09:47:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-disease-information-sheet-for-category-4-returnees-from-an-ebola-affected-3451106449dc4cbd 2026-09-09T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-disease-information-sheet-for-category-3-returnees-from-an-ebola-affected-66d6f6455dcf6d66 2026-09-09T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-disease-information-sheet-for-category-2-returnees-from-an-ebola-affected-0ad9eb86ec575c6f 2026-09-09T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-disease-information-sheet-for-category-1-returnees-from-an-ebola-affected-24c7b8b02c106176 2026-09-09T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-and-marburg-contact-matrix-for-returning-workers-scheme-and-non-uk-exposur-dedb115fc574e9fe 2026-09-09T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-virus-disease-clinical-management-and-guidance-74343e283fe62dbc 2026-09-09T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-returning-workers-scheme-public-health-advice-3f98a3a732b6c31c 2026-09-09T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/barclays-upgrades-sagimet-stock-rating-on-acne-drug-potential-ae3e9d55d7da7baa 2026-09-09T08:08:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/oral-infigratinib-shows-meaningful-benefits-beyond-growth-within-52-weeks-in-chi-0c539f69c1cd457c 2026-09-09T08:04:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-sleep-apnea-measure-rose-10-4-with-an-experimental-drug-versus-49-2-with-place-90e8edbb76843343 2026-09-09T08:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mosliciguat-advances-to-phase-3-phrontier-trial-after-phocus-study-shows-20-pvr-7689bcdaf1ae338a 2026-09-09T07:34:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/proteomic-aging-clocks-just-changed-what-a-phase-2a-trial-has-to-prove-2ad189fe17c2661b 2026-09-09T07:34:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/medicine-shortages-grow-in-iran-as-us-tightens-sanctions-blockade-ecd987fe722f5a4e 2026-09-09T07:20:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/5-questions-that-could-determine-alzheimer-s-next-chapter-16943d6949229332 2026-09-09T07:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-cracks-down-on-food-safety-violators-5fff85b007469683 2026-09-09T06:07:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-suspends-food-licenses-of-railway-catering-supplier-20-eateries-c5fd85665f97fc76 2026-09-09T06:02:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/steady-stream-of-crossover-rounds-stock-biotech-s-ipo-pipeline-dbbe4746af7c54ed 2026-09-09T04:17:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/ibento-ibento-report-on-the-pmda-hokuriku-branch-10th-anniversary-symposium-c1a0e57e7ec099d8 2026-09-09T03:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/rezubio-doses-first-patients-in-phase-i-trial-of-inhaled-respiratory-drug-rz-520-378d2a6eb465cc4d 2026-09-09T02:34:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/taiwan-s-obigen-pharma-to-unblind-phase-3-botox-trial-early-in-november-year-end-af705b30fbefc4cc 2026-09-09T02:26:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/rezubio-doses-first-patients-in-phase-i-trial-of-inhaled-respiratory-drug-rz-520-1026a08765283c42 2026-09-09T02:01:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/wegovy-and-mounjaro-for-weight-loss-not-funded-a2a3ffb1738d2e00 2026-09-09T02:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/shinhan-securities-cuts-alteogen-target-to-520-000-after-novartis-aoc-phase-3-fa-972a02956e1cfc51 2026-09-09T01:25:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/many-different-paths-may-lead-to-a-role-in-clinical-project-management-96598feaeb50c516 2026-09-09T00:39:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/click-e-stock-one-novartis-new-drug-fails-phase-3-target-price-for-alteogen-lowe-7cafc5a1c226a35d 2026-09-09T00:23:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/novo-nordisk-filed-form-6-k-9e8f3bd2a58b229c 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gsk-filed-form-6-k-0a518003195b02c6 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/temporary-policies-for-compounding-certain-starter-parenteral-nutrition-drug-pro-bff9d18f307f05a1 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vaccines-and-related-biological-products-advisory-committee-notice-of-meeting-es-b6fb3f98dd33049b 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-hum-9e81e95c6000ebb0 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/privacy-act-of-1974-system-of-records-99f349f787d2f97e 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/determination-of-regulatory-review-period-for-purposes-of-patent-extension-andem-d38ea0d42ee8ba36 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-pre-8f9c9e790ba2b6a8 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/determination-of-regulatory-review-period-for-purposes-of-patent-extension-anzup-eeb61cd6a595bf0b 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ankti-9840243fd9e98d18 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-vaccine-injury-compensation-program-list-of-petitions-received-bee1e53401727a8f 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/reorganization-of-the-national-center-for-immunization-and-respiratory-diseases-588d95ecfd03eea8 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-mucinex-fast-max-liquid-gels-day-night-cold-and-flu-95e4942fca23d639 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-donepezil-178586cc38e5c316 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-zinc-oxide-3cd24fc4898f8e23 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-oxycodone-hydrochloride-40f2b893ea5c9a89 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-nighttime-sleep-aid-berry-flavor-6323e5aee114edcd 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-head-and-shoulders-bare-minimal-ingredients-pure-clean-2in1-cded6e31a1e01ccf 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-mucus-relief-cold-flu-and-sore-throat-maximum-strength-8a6c0d65c6afe6c4 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-scopolamine-f1a02fb6bd212fe9 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-pramipexole-dihydrochloride-5f9b5f685b87ac04 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-omeprazole-c5d97c29ca36bcdd 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-drx-choice-children-daytime-cough-and-chest-congestion-63b91d6ec40856ad 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-meclizine-hydrochloride-507cf52bc773bd0a 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-eczema-soothing-moisturizing-cream-14fdbfbd047c6287 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-advanced-healing-345f66e1cadf5176 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-antibacterial-lotions-skin-cleanser-8d113cdbd3dee527 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-theratears-7443966d80f89fae 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-levothyroxine-sodium-bf4d0a9fa3c76075 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-dexamethasone-sodium-phosphate-db4b052a55894258 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-colgate-maxfresh-knockout-773ccc8e9a5ccb0c 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-bumetanide-0247a524324ef1b4 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-amlodipine-besylate-and-benazepril-hydrochloride-a8908cc07cab864a 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-spironolactone-62d6369d502689be 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-ibuprofen-3bdfa3f85fe9337e 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-senokot-99e4f6f0b2bd039d 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-nicotine-5815f3f89a82e8bd 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-bendamustine-hydrochloride-e0bd4b81923aebd2 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-metformin-a9fba3d11a436817 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-unspecified-product-b0cd29572992f66b 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tips-for-dealing-with-empty-nest-syndrome-64aa3c260d31a871 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cleveland-clinic-partners-with-luminai-to-transform-health-system-operations-8b1951904a6aedef 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-microbiological-efficacy-of-the-antibacterial-drug-fluorothiazinone-4649c521622754f8 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-70-000-reassessing-the-global-fontan-population-through-citation-chain-an-b1ba1fb432aad77c 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/estimating-and-predicting-clinical-trial-outcomes-in-china-f00f8b31650910e0 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/intranasal-midazolam-vs-mouth-dissolving-clobazam-in-terminating-seizures-a-rand-99ac18ed68820c9c 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/associations-of-baseline-neutrophil-to-lymphocyte-ratio-with-efficacy-and-toxici-c96f347b709d5107 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/neoadjuvant-pertuzumab-biosimilar-hlx11-versus-reference-pertuzumab-for-early-st-7808b92e0e1149cf 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/unveiling-novel-transcriptomic-prognostic-biomarkers-for-specific-breast-cancer-42d2894e98971e23 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/therapeutics-candidates-and-repurposing-strategies-to-target-parkinson-s-disease-96683c528f323412 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/neo-adjuvant-approvals-for-solid-tumors-by-the-us-food-and-drug-administration-2-756ed3abf614efc6 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-phase-3-trial-of-vosoritide-in-children-with-hypochondroplasia-6de4f09ea4b05915 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/regulatory-and-scientific-challenges-in-pediatric-oncology-d3b46ab83794e42f 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-of-i-helicobacter-pylori-i-infection-with-insulin-resistance-tumor-n-316790c378779761 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/phenomenology-in-pediatric-nursing-lessons-from-studies-of-mothers-caring-for-ch-4f3fffea388d6bfe 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/utilizing-a-smartphone-application-for-perinatal-depression-screening-and-care-l-d1657f9c0ce56b10 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/network-biology-to-artificial-intelligence-building-the-next-generation-of-predi-7049814c4b1b0ea9 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/interactions-of-nanoparticles-with-structures-of-the-respiratory-system-nanopart-6e7d20d5c4593f8d 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/inhaled-nanoliposomes-for-treating-lung-disease-including-a-case-study-of-amikac-5c581901e1fef964 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-delivering-particles-aim-to-breach-the-blood-brain-barrier-6b0773077796d0f1 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mechanical-basis-of-cortical-cataract-214599f9167e95ce 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07811128-leveraging-digital-health-solutions-to-collect-patient-reported-outc-de9c163ffaa5b58e 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07810855-using-bedside-ultrasound-to-understand-fluid-management-in-patients-f01e5454fd815262 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07810231-prospective-longitudinal-cohort-study-of-implant-age-pocket-plane-in-f1335f5a7fd090e7 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07809542-brain-network-characteristics-of-pain-patients-based-on-magnetoencep-f1102e08355c2f4a 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07809438-a-comparative-performance-study-between-high-and-standard-resolution-a7b9283bcd325474 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07809399-volumetric-hrct-in-stable-copd-patients-905336f1346cda49 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07809087-feasibility-study-of-an-interactive-wall-based-intervention-program-68f2eb96ca9dbf6e 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07809074-mindfulness-and-self-compassion-intervention-for-ostomy-patients-due-928772f3ba63ee88 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07808645-wearable-sleep-eeg-and-auditory-stimulation-in-healthy-adults-a3f895f1435a9f4e 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07803471-yiqi-fumai-lyophilized-injection-for-chronic-heart-failure-caused-by-a2f07156d8dd8c5f 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07796373-nemtabrutinib-for-chronic-lymphocytic-leukemia-cll-small-lymphocytic-38cf1b9c433f4464 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07770919-continuous-theta-burst-stimulation-for-generalized-anxiety-disorder-a11ec2e143861103 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07755748-glaucoma-screening-to-enhance-at-risk-californians-health-survey-res-613aad5046be38a3 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07686380-il-15-superagonist-with-or-without-vaccine-in-biochemically-recurren-cfd5e39e4ab2fd00 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07668518-a-study-of-the-safety-tolerability-pharmacokinetics-and-efficacy-of-53495f0e626ad570 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07667400-docetaxel-and-sx-682-in-recurrent-metastatic-head-and-neck-squamous-eb782075b524b62c 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07645443-feel-good-a-multicenter-trial-of-a-mindfulness-based-group-therapy-i-e6b3a6106587bc2a 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07524530-stem-cell-transplantation-for-participants-with-germline-runx1-assoc-f7c7537ec91ee762 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07509034-autologous-b7-h3-chimeric-antigen-receptor-t-cells-in-previously-tre-2b314a9db8642130 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07447557-study-of-intrathecal-elp-02-for-charcot-marie-tooth-disease-type-4j-9df85b59b7760510 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07436728-a-study-of-tak-505-in-adults-with-solid-tumors-0ceaf12c08fe7644 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07262983-evaluating-the-safety-and-tolerability-of-baricitinib-in-patients-wi-834c49c5b61fdd2a 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07241377-a-study-in-healthy-adults-to-compare-the-bioavailability-of-epa-dha-04a145623e5fd712 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07234942-a-study-to-investigate-the-safety-tolerability-pharmacokinetics-and-934403a64baf19fb 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07224763-study-to-evaluate-the-safety-and-efficacy-of-the-ggta1-ko-thymokidne-e7469684f1a340a9 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07210398-mindfulness-based-cognitive-therapy-for-the-chronic-pain-early-cogni-a5c8ad0779df2ad7 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07205107-clindamycin-phosphate-adapalene-and-benzoyl-peroxide-triple-combinat-c2ef75272e264556 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07166094-study-to-assess-the-efficacy-and-safety-of-rina-s-compared-to-treatm-654bf6bd00153589 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07137442-distinguishing-tics-and-functional-tics-using-clinical-neurophysiolo-e0a0f7cc00953d72 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06851806-study-of-palivizumab-in-children-with-high-risk-of-severe-respirator-030ea64e3955972a 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06825702-safety-tolerability-and-efficacy-of-intravitreal-kio-104-in-patients-8d4299ce7f4765dc 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06782308-tinnitus-patient-preferences-survey-717b4fa3f14c3c2b 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06578520-effect-of-the-use-of-dapagliflozin-in-patients-with-refractory-heart-ed2d60e95fd26467 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06548412-ctx-009-with-gemcitabine-cisplatin-and-durvalumab-as-first-line-ther-2b2fdba90bbebbba 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06470048-a-clinical-study-to-evaluate-ianalumab-in-participants-with-diffuse-81b10aa4165bd17c 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06410248-triapine-in-combination-with-temozolomide-for-the-treatment-of-patie-0cf1d97b4e719323 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06323161-a-research-study-to-see-how-much-cagrisema-lowers-blood-sugar-and-bo-7b5290a15f28fde0 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06260228-home-based-self-management-and-cognitive-training-changes-lives-hobs-ff1e48edbb3a2369 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06235801-a-phase-i-ii-study-of-gilteritinib-and-momelotinib-for-patients-with-1fe17411a66cc840 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06052631-microneurographic-assessment-of-peripheral-nerves-in-healthy-volunte-19ef87b4db826563 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05706558-retrospective-review-of-esophageal-cancer-at-mskcc-cafd4ee1a7b70879 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05570253-a-study-of-sdx-7320-in-combination-with-eribulin-for-people-with-bre-7c04db2a9102a2ce 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05232071-placebo-controlled-proof-of-concept-study-to-evaluate-the-safety-and-9fcfbde442103736 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05037461-precision-radiotherapy-using-mr-linac-for-pancreatic-neuroendocrine-fcedc2d84f591031 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04847648-air-polishing-in-the-treatment-of-peri-implantitis-7fadfb7a67b10d53 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04542824-trial-of-the-safety-and-efficacy-of-epcoritamab-in-japanese-subjects-8f8b2e5edddf7421 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04124497-a-trial-for-relapsed-and-relapsed-refractory-multiple-myeloma-patien-96886e54e668bcc6 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03625037-first-in-human-fih-trial-in-patients-with-relapsed-progressive-or-re-7c8817969428243d 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03549754-icareme-global-registry-multinational-real-world-evidence-in-cardior-ca8b38986b5aecf0 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03307109-quality-of-life-in-patients-having-a-prosthetic-joint-infection-2572312124caf8f4 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct02890329-ipilimumab-and-decitabine-in-treating-patients-with-relapsed-or-refr-cc9d070597ff8255 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct02767011-tele-health-electronic-monitoring-to-reduce-post-discharge-complicat-c84b8d01820bce9e 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01568658-genetic-and-physical-study-of-childhood-nerve-and-muscle-disorders-f16cdfe7ad322553 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/moderna-begins-phase-1-clinical-trial-of-ebola-vaccine-against-strain-behind-drc-27bba2ce08cb2b5c 2026-09-08T23:53:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-trial-wins-sent-roivant-and-pharvaris-higher-98c19d328893c1ff 2026-09-08T23:38:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/as-fda-sets-ai-principles-for-drug-development-how-much-evidence-is-enough-a883e1c3fce040a0 2026-09-08T22:40:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/trump-administration-names-permanent-leaders-at-fda-amid-ongoing-controversies-b3c82c9c2a34e326 2026-09-08T22:38:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharvaris-stock-jumps-after-positive-hae-drug-t-4085528d18522778 2026-09-08T21:57:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/appeals-court-to-rule-soon-on-marijuana-rescheduling-as-billions-in-cannabis-tax-e164d6e9b92848d2 2026-09-08T21:19:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/semaglutide-improves-bmi-category-in-phase-3-pediatric-obesity-trial-0a553bf6e7f7c09b 2026-09-08T20:17:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/novo-nordisk-a-s-stock-nvo-closed-down-by-3-09-on-sep-8-facts-behind-the-movemen-bf3c0573fb832069 2026-09-08T20:15:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/hhs-announces-key-leadership-selections-at-fda-to-promote-innovation-reform-and-da223f20305656e3 2026-09-08T19:59:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/appeals-court-to-rule-soon-on-marijuana-rescheduling-as-billions-in-cannabis-tax-53e03398fc5994dc 2026-09-08T19:33:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/quantum-biopharma-s-lucid-ms-gets-fda-clearance-for-phase-2-trial-in-multiple-sc-6e1a50fab04737c7 2026-09-08T18:13:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/amgen-falls-10-as-novartis-trial-failure-clouds-a-cholesterol-drug-class-nvs-sto-577262ea46adae76 2026-09-08T17:08:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-suffers-third-clinical-setback-in-a-week-wiping-out-over-40-billion-in-aecba47d0f5a987e 2026-09-08T16:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-a-cannabis-business-is-betting-on-dogs-to-reach-fda-approval-e63e12a392c30ad2 2026-09-08T16:29:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/pneumococcal-vaccination-for-older-adults-and-for-individuals-in-a-clinical-risk-a3c9fa73d91e326d 2026-09-08T15:28:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/house-advances-carter-s-bipartisan-bill-to-reduce-animal-testing-in-drug-develop-f90a2c9708224bfc 2026-09-08T15:28:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-enforces-zero-tolerance-with-major-food-safety-crackdown-a0e97e5aa54ea452 2026-09-08T15:25:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/nuevos-proyectos-de-consulta-para-la-opinion-publica-f60c4dde925aa14a 2026-09-08T15:16:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-cholesterol-lowering-medicine-fails-phase-3-clouding-lp-a-horizons-1b5ea32d857530a1 2026-09-08T14:52:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/green-shoots-for-uk-pharma-investment-but-delivery-will-decide-whether-they-take-a66e726a10440e23 2026-09-08T14:47:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/ionis-pharmaceuticals-gets-85-price-target-des-88a596b142c0403e 2026-09-08T13:49:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/x4-pharma-gains-fda-agreement-to-cut-phase-3-trial-size-to-76-patients-86a2f6c69c45444e 2026-09-08T13:20:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/exozymes-selects-curia-as-commercial-scale-manufacturing-partner-for-nct-e32fe23efc672768 2026-09-08T13:05:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/imdelltra-in-combination-with-imfinzi-demonstrated-landmark-improvement-in-overa-2f50edcb3c7d5463 2026-09-08T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-2025-46183ecdfec674cc 2026-09-08T12:46:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/annual-flu-programme-8d7750db1c23f662 2026-09-08T12:44:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/wegovy-for-overweight-young-children-novo-nordisk-s-obesity-drug-shows-effective-3431f97d0f9e3263 2026-09-08T12:30:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/veru-advances-oral-sabizabulin-following-positive-preclinical-data-showing-poten-3888551e81843663 2026-09-08T12:28:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/liver-cancer-patients-appear-to-be-living-longer-in-a-can-fite-trial-4dcb429a7fce4ae3 2026-09-08T12:20:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vor-biopharma-vor-completes-enrollment-in-phase-3-trial-as-market-eyes-growth-po-6854d0a7bff59ab1 2026-09-08T12:18:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/enregistrement-des-antibiotiques-dans-vamreg-e-learning-pour-les-veterinaires-5fb5bf0d85ad7573 2026-09-08T12:16:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-12b-avidity-acquisition-hits-phase-3-speedbump-as-dystrophy-drug-disapp-81a38543b41b14c8 2026-09-08T12:12:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/xfor-gains-fda-nod-for-reduced-trial-size-in-pivotal-phase-3-study-dfe6bf454bee75c8 2026-09-08T12:10:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/tozorakimab-demonstrated-statistically-significant-and-highly-clinically-meaning-4a747bc53373c024 2026-09-08T11:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biovie-announces-next-stage-of-fda-engagement-for-phase-3-parkinson-s-disease-pr-86f2e64a80edb748 2026-09-08T11:41:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/artiva-biotherapeutics-announces-planned-2026-data-readouts-and-phase-3-trial-in-d72d6fed3e722f8c 2026-09-08T11:41:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nature-medicine-features-a-briacell-trial-among-11-shaping-medicine-in-2026-a2c3aef4540443f1 2026-09-08T11:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biovie-seeks-fda-feedback-on-a-proposed-parkinson-s-trial-of-about-175-patients-ee88e950491954eb 2026-09-08T11:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/briacell-s-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-can-339c6a459d143c72 2026-09-08T11:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/oncologists-say-newly-approved-pancreatic-cancer-drug-is-a-breakthrough-for-trea-81381f05106e10cb 2026-09-08T11:26:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/okyo-pharma-nasdaq-okyo-readies-phase-3-trial-of-eye-pain-drug-urcosimod-90d050241783edad 2026-09-08T11:01:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-50-million-payment-is-coming-to-monte-rosa-as-novartis-starts-a-sjogren-s-tria-31715f4d196d2209 2026-09-08T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-new-trial-for-eye-related-muscle-weakness-is-planned-for-2027-vor-bio-finished-b45892b2c443c86f 2026-09-08T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bristol-myers-squibb-announces-positive-topline-results-from-registrational-phas-8624811f3ce076b9 2026-09-08T10:59:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/merck-to-participate-in-the-morgan-stanley-24th-annual-global-healthcare-confere-e76ae3336b1268bc 2026-09-08T10:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vaccine-update-30d4e36f5ec7eb5a 2026-09-08T10:02:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/vaccine-update-issue-375-flu-special-2026-1a30d6fa07e93be8 2026-09-08T10:01:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/up-to-200-000-people-live-with-this-lung-disease-roivant-starts-a-new-trial-d037a53d1ec5911f 2026-09-08T10:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tukaram-mundhe-s-fda-steps-up-drug-crackdown-in-maharashtra-complaints-jump-557-ecfe5acba6850e4a 2026-09-08T09:56:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-12bn-avidity-bet-falters-on-late-stage-del-desiran-flop-a07058258a6406e4 2026-09-08T09:51:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/2026-0170da8a7075e9e1 2026-09-08T09:40:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-heart-drug-fails-phase-3-trial-cutting-genetic-ch-0570ea9380fbcdd9 2026-09-08T09:39:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/2026-2b2822c02a7f5c39 2026-09-08T09:35:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/prac-d8971a24133f87f2 2026-09-08T09:07:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/characteristics-of-people-infected-with-toxigenic-c-ulcerans-74755f86c69d844a 2026-09-08T08:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/ukhsa-evidence-reviews-8f54ff16e8d4cd78 2026-09-08T08:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/ame-bridge-management-1a3a141ab51144fc 2026-09-08T08:16:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharma-major-novartis-falls-10-after-three-drug-trial-setbacks-92f853f4d5272a6c 2026-09-08T07:51:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/upstream-bio-presents-results-from-the-phase-2-valiant-trial-of-verekitug-for-th-e4bacc39df389b5c 2026-09-08T07:40:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/upstream-bio-reports-phase-2-valiant-trial-results-showing-verekitug-reduced-sev-18afce1d16ed54f2 2026-09-08T07:40:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-stock-slides-as-centerpiece-of-12b-avidity-buyout-flunks-crucial-phase-369fe1ae5d30a5c0 2026-09-08T07:34:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-quarterly-dose-cut-asthma-flare-ups-56-versus-a-dummy-treatment-upstream-bio-p-5957ae35a18b8b3f 2026-09-08T07:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tukaram-mundhe-effect-100-days-12-083-actions-as-maharashtra-fda-leads-biggest-s-d98c23d18ab152bc 2026-09-08T06:42:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/food-safety-chief-tukaram-mundhe-s-plan-for-festivals-in-maharashtra-8c168d932d6ebed2 2026-09-08T05:32:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/newron-reports-subscription-for-eur-5-5-million-of-shares-by-investor-group-as-p-9cedb9c94f3df816 2026-09-08T05:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-data-says-about-tukaram-mundhe-s-100-day-stint-as-fda-commissioner-196f7cd7d48755cb 2026-09-08T04:03:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/bmc-medical-co-ltd-recalls-luna-g3-apap-model-lg3600-with-firmware-g3-2-00-76-du-49c4827bc368c793 2026-09-08T04:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-inspections-expose-drug-safety-gaps-e2b63ad181bd692b 2026-09-08T03:20:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/yakkyokukata-jp-drafts-september-2026-part-1-posted-58fb2b9570d86ac0 2026-09-08T03:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/yakkyokukata-jp-drafts-september-2026-part-2-posted-7fc8f7827c7927a1 2026-09-08T03:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-3c9bb893b8f5ebb3 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gsk-filed-form-6-k-d43e989b55ee68c6 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-filed-form-6-k-9a3be5d9cea2290a 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mark-allen-d-d-s-rescission-of-final-agency-action-and-withdrawal-of-order-to-sh-4ff464311d7f3296 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-public-comment-requ-ba5586ce8851a924 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medicare-program-town-hall-meeting-on-the-fiscal-year-2028-applications-for-new-e0882cd256184bcf 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/proposed-data-collection-submitted-for-public-comment-and-recommendations-51525e15cfb1b3ee 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/center-for-scientific-review-amended-notice-of-meeting-945ea22744a88fc9 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bulk-manufacturer-of-controlled-substances-application-irvine-labs-inc-06b927a4afc4595e 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/importer-of-controlled-substances-application-fisher-clinical-services-inc-4f126cd097473cf8 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/importer-of-controlled-substances-application-cambrex-high-point-inc-e82f843236b1838a 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/importer-of-controlled-substances-application-fresenius-kabi-usa-llc-a380373346bbc5af 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/stephen-bossenberry-m-d-decision-and-order-a19b15ba4f04fad0 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/importer-of-controlled-substances-application-andersonbrecon-inc-dba-pci-pharma-58475345f958d070 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-33d1d408902e2bdd 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/submission-for-omb-review-30-day-comment-request-data-and-specimen-hub-dash-euni-43d65c3b310c33ea 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-baloom-2-panthenol-hydro-airy-sunscreen-76166a8e1258bb36 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-jack-black-sun-guard-sunscreen-spf45-11d1342f09fc9fc4 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-gas-relief-mint-flavor-b180d559ff2535ed 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-henry-schein-povidone-iodine-prep-pad-81fbd0914690a99f 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-gocovri-82a404236e5a1a35 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-mucus-relief-severe-congestion-and-cough-f710e7b1445ced68 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-remedy-antifungal-with-olivamine-51fd828d06101007 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-intense-therapy-lip-balm-basil-lemon-11c1c2c0cb6eab1b 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-fiber-laxative-6fe5768eb18749f6 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-ibuprofen-0ab98dedd1f109b5 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-rizatriptan-benzoate-9cb7cd03cb346b6c 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-temazepam-1493397ecc75f9a7 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-telmisartan-and-hydrochlorothiazide-38097fca411de6b8 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-freshmint-premium-anticavity-6130335239e19fe8 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-fluticasone-propionate-and-salmeterol-diskus-90cafa84bcde75b2 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-jack-black-intense-lip-therapy-spf25-black-tea-and-blackberry-22eb3fa7f4dac033 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-ibuprofen-minis-e7d71de53a87003d 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-medline-e5f6e808cb6975c6 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-unspecified-product-63f74e54e64d4b8f 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-intense-therapy-lip-balm-pineapple-mint-4b142735c95284f8 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-thyroid-support-113e8b12e807cefd 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-dapagliflozin-34b4fff388ddc511 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-pepto-bismol-fast-melts-fresh-berry-flavored-f616d20ad8daef35 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-imatinib-mesylate-893a33ea1b0588f5 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-vicks-zzzquil-nighttime-sleep-aid-diphenhydramine-hcl-free-of-192ef96369f04157 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-clonidine-hydrochloride-f79a41c83c300454 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-prednisone-08ef9ceeba00368e 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/should-kids-have-mental-health-days-b366f95b902dfefd 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/united-therapeutics-corporation-announces-accelerated-share-repurchase-agreement-d3b6ea9ca8945a2a 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bausch-health-and-yun-announce-expansion-to-mexico-and-across-additional-emea-ma-f40b7d30c789ecd7 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pr-siliq-brodalumab-injection-now-reimbursed-under-alberta-s-public-drug-plan-im-e79ea40f76db38fd 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/outcome-definitions-in-clinical-trial-registrations-a-cross-sectional-study-80ea0dc761f2ea79 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/adaptive-ai-based-mobile-simulation-for-drug-calculation-competency-in-nurses-a-a38487112b01837a 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/safety-pharmacokinetics-and-pharmacodynamics-of-the-glp-1-gip-gcg-receptor-agoni-732b3a954859f846 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/butylphthalide-combined-with-tenecteplase-in-mild-disabling-acute-ischaemic-stro-8632aa90834b8816 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/systematic-review-and-meta-analysis-of-intrathecal-drug-delivery-systems-for-the-78fe51bd2837a2ad 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/randomised-phase-iii-trials-of-cancer-prevention-drugs-a-systematic-review-and-p-e0ab6c687137bfcb 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-bayesian-phase-i-ii-trial-design-to-optimizing-dose-schedule-regimen-with-comp-2fe1ae9d0f6e2108 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-various-types-of-remineralizing-agents-on-the-remineralization-of-mild-6e735d880cd42199 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparison-of-microdrop-administration-using-a-bottle-adapter-of-2-5-phenylephri-1bd95ea7d3830788 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/notifiable-diseases-causative-agents-reports-for-2026-32900b46450305d4 2026-09-07T15:38:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/medicines-eligible-for-northern-ireland-mhra-authorised-route-ea4846a98bf6c2a7 2026-09-07T14:03:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/only-around-half-of-primary-school-children-got-their-flu-vaccine-last-year-403f49a5bd04d397 2026-09-07T11:44:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/2-2026-3c227aa9e7354928 2026-09-07T11:21:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/tobacco-and-vapes-packaging-appearance-and-display-b0f65b22298b2fc9 2026-09-07T11:19:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/2026-a3d36d0f75424a9d 2026-09-07T11:11:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/mdd-class-i-ndi-passive-sphere-b7d0605889498eca 2026-09-07T10:03:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-41-report-data-to-week-40-dat-57a8ff892a5702f4 2026-09-07T09:40:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-4-october-2026-3416de2db5fbba30 2026-09-07T09:40:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-european-joint-programme-on-rare-diseases-d53cc8321f2dea5f 2026-09-07T09:40:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-harmonised-approach-to-early-feasibility-studies-for-medical-devi-0fb60975f2bf9da6 2026-09-07T09:40:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-41-report-data-to-week-40-data-up-t-544b20cee08c6ce5 2026-09-07T09:32:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-healthy-adaptation-to-pregnancy-postpartum-and-parenthood-82c4989530fdfda2 2026-09-07T09:25:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-lpt-laser-based-proton-therapy-syslpt-laser-based-proton-therapy-6966003adb9cf5cc 2026-09-07T09:24:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/driving-digital-transformation-amanda-strydom-on-women-technology-and-leadership-b25e6893da42d72b 2026-09-07T09:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-protection-in-children-and-young-people-s-settings-including-education-cca215b8fd3fb49b 2026-09-07T08:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/amarin-group-esg-3-9-ftse-russell-ea572dc6a605d4a4 2026-09-07T07:35:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-37-report-data-to-week-36-dat-12867e0648495a43 2026-09-07T06:58:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/11-jbda-1e862f8e99770ad1 2026-09-07T06:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/research-achievement-related-to-chugai-originated-nemolizumab-receives-the-11th-698ca4f032fd30e5 2026-09-07T06:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-hand-sanitizer-vanilla-frosting-502a8098e1a85c7c 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-nadolol-9ecde2dfb8ab0283 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-american-safety-and-first-aid-triple-antibiotic-73419f5abf1f0e8e 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-american-safety-first-aid-a829d4721e66769d 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-lady-speed-stick-24-7-fresh-fusion-3cc457ca2f39b640 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-hydrating-mist-hand-sanitizer-with-silicone-keychain-holder-be-864d678e71f2b91f 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-medi-first-topical-analgesic-3c8148ed4f999e88 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-pain-relieving-lidocaine-patch-bf93f3783ab22813 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-candesartan-cilexetil-b916f82c8372ddec 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-mycophenolate-mofetil-b26da168ebd7aaa8 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-hydrating-mist-hand-sanitizer-with-silicone-keychain-holder-si-9ffe521131db9c95 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-hsenjt-arnica-bruise-cream-3f2dbcb573a9d9c2 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-hsenjt-antifungal-cream-b03d186973378fab 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-bzk-antiseptic-towelette-7757b41c536188cf 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-sting-relief-pad-b2fae5b78e3baa71 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-alcohol-prep-pads-medium-sterile-06e2f1ee977c552c 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-unspecified-product-3a33edb2c5e2a501 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-speed-stick-power-ultimate-sport-7bc931b75bd52c25 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-hand-sanitizer-cherry-sundae-d156d9e332eb3a64 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/survey-reveals-how-social-media-influences-men-s-health-pkg-329128b04c75c02f 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nanoparticle-based-strategies-to-enhance-psma-targeted-radioligand-therapy-a-rev-635a306c2914999f 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integration-of-proteomic-aging-clocks-in-a-phase-2a-clinical-trial-supports-simu-7be6a31c09a0d1b6 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/salovum-reduces-mortality-in-isolated-severe-traumatic-brain-injury-a-randomized-f5280cc30cebfe6c 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/use-of-the-bacterial-lysate-om-85-for-the-primary-prevention-of-wheezing-lower-r-daaaa4b1cdcd0cc5 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/assessment-of-lebanese-community-pharmacists-perceptions-and-practices-towards-p-29b4dbe8992d3edd 2026-09-07T00:00:00.000Z weekly 0.7